

CITATION REPORT

List of articles citing

Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members

DOI: 10.1001/jama.2014.10517

JAMA - Journal of the American Medical Association, 2014, 312, 1033-48.

Source: <https://exaly.com/paper-pdf/57652601/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1027	Disorders of Red Blood Cells: Anemias. 2008 , 885-921		
1026	Elevated pulse pressure is associated with hemolysis, proteinuria and chronic kidney disease in sickle cell disease. 2014 , 9, e114309		22
1025	Five hematologic tests and treatments to question. 2014 , 2014, 599-603		7
1024	Nitric oxide-based treatment for sickle cell leg ulcers?. 2014 , 1, e86-7		5
1023	From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. 2014 , 93, e215		49
1022	Five hematologic tests and treatments to question. 2014 , 124, 3524-8		44
1021	Tous les patients se présentant aux urgences pour crise vaso-occlusive sont-ils drpanocytaires ? Étude rtrospective au CHU de Toulouse. 2015 , 36, A72-A73		
1020	Interventions for treating intrahepatic cholestasis in people with sickle cell disease. 2015 , CD010985		9
1019	Optimizing hydroxyurea therapy for sickle cell anemia. 2015 , 2015, 436-43		32
1018	Evidence gaps in the management of sickle cell disease: A summary of needed research. 2015 , 90, 273-5		29
1017	Increased risk of severe vaso-occlusive episodes after initial acute chest syndrome in children with sickle cell anemia less than 4 years old: Sleep and asthma cohort. 2015 , 90, 371-5		15
1016	Age-dependent pathophysiology of acute chest syndrome in children with sickle cell disease. 2015 , 90, 367-8		2
1015	2015 Clinical trials update in sickle cell anemia. 2015 , 90, 934-50		27
1014	Psychological therapies for sickle cell disease and pain. 2015 , CD001916		23
1013	Prenatal Diagnosis of the Hemoglobinopathies. 2015 , 718-754		
1012	NHLBI Strategic Visioning: setting an agenda together for the NHLBI of 2025. 2015 , 125, 2733-5		1
1011	MAGiC: VOC remains but kids with SCA appear. 2015 , 126, 1637-8		2

1010	Adjunctive therapy with inhaled nitric oxide for severe acute chest syndrome in patients with sickle cell disease. 2015 , 41, 2213-5	0
1009	SIKKELCELZIEKTE. 2015 , 31, 510-523	
1008	Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment. 2015 , 62, 1956-61	97
1007	Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial. 2015 , 90, 1099-105	43
1006	How we prevent and manage infection in sickle cell disease. 2015 , 170, 757-67	17
1005	Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study. 2015 , 95, 545-50	22
1004	Sickle cell disease: wheeze or asthma?. 2015 , 1, 14	9
1003	Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. 2015 , 90, 1135-41	51
1002	How I manage cerebral vasculopathy in children with sickle cell disease. 2015 , 170, 615-25	24
1001	Blood transfusion and 30-day readmission rate in adult patients hospitalized with sickle cell disease crisis. 2015 , 55, 2331-8	15
1000	The ASPHO 2015 Distinguished Career Award goes to Dr. Winfred C. Wang, MD. 2015 , 62 Suppl 2, 19-20	
999	The trials and hopes for drug development in sickle cell disease. 2015 , 170, 768-80	24
998	Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia. 2015 , 62, 184-185	14
997	National Heart, Lung, and Blood Institute Strategic Visioning: setting an agenda together for the NHLBI of 2025. 2015 , 105, e25-8	17
996	Fetal hemoglobin level and nutritional status in patients with sickle cell disease. 2016 , 15, 63	1
995	Sickle cell disease in the ICU. 2015 , 21, 569-75	6
994	Pulmonary hypertension in sickle cell disease. 2015 , 21, 432-7	7
993	Update of hematopoietic cell transplantation for sickle cell disease. 2015 , 22, 227-33	29

992	Pulmonary function indices in children with sickle cell anemia in Enugu, south-east Nigeria. 2015 , 36, 928-34	3
991	Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia. 2015 , 6, 285-90	4
990	Biomarkers and recent advances in the management and therapy of sickle cell disease. 2015 , 4,	4
989	Considerations of red blood cell molecular testing in transfusion medicine. 2015 , 15, 1455-64	12
988	NHLBI strategic visioning: setting an agenda together for the NHLBI of 2025. 2015 , 191, 489-91	8
987	Association between Hospital Volume and Within-Hospital Intensive Care Unit Transfer for Sickle Cell Disease in Children's Hospitals. 2015 , 167, 1306-13	4
986	Protein Folding: From Normal Cellular Function to Pathophysiology. 2015 , 89-103	
985	Sickle cell disease: renal manifestations and mechanisms. 2015 , 11, 161-71	184
984	Le syndrome thoracique aigu : complication pulmonaire aiguë des patients adultes atteints d'un syndrome drpanocytaire majeur. 2015 , 24, 71-77	0
983	National Heart, Lung, and Blood Institute (NHLBI) strategic visioning: setting an agenda together for the NHLBI of 2025. 2015 , 65, 1130-3	6
982	Transfusion Medicine in Sub-Saharan Africa: Conference Summary. 2015 , 29, 195-204	11
981	Sickle Cell Trait from a Metabolic, Renal, and Vascular Perspective: Linking History, Knowledge, and Health. 2015 , 2, 330-5	8
980	A Mixed-Methods Study of Pain-related Quality of Life in Sickle Cell Vaso-Occlusive Crises. 2015 , 39, 305-9	4
979	Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease. 2015 , 85, 424-32	13
978	National heart, lung, and blood institute (NHLBI) strategic visioning: setting an agenda together for the NHLBI of 2025. 2015 , 131, 1106-9	4
977	How I treat and manage strokes in sickle cell disease. 2015 , 125, 3401-10	85
976	Hematopoietic Cell Transplantation and Sickle-Cell Disease: An Option for Everyone?. 2015 , 3, 146-153	
975	How I treat priapism. 2015 , 125, 3551-8	32

974	Impact of epigenetic mechanisms on therapeutic approaches of hemoglobinopathies. 2015 , 55, 95-100	11
973	Management of patients with sickle cell disease. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 91	27.4 2
972	Risk Factors for Attention and Behavioral Issues in Pediatric Sickle Cell Disease. 2015 , 54, 1087-93	9
971	Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. 2015 , 8, 372	13
970	Hydroxyurea therapy for sickle cell anemia. 2015 , 14, 1749-58	99
969	Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice. 2015 , 55, 363-72	23
968	Increasing prevalence of thalassemia in America: Implications for primary care. 2015 , 47, 592-604	33
967	Expression Pattern of HIF-1 α and VEGF Supports Circumferential Application of Scatter Laser for Proliferative Sickle Retinopathy. 2016 , 57, 6739-6746	16
966	Stable-Isotope Dilution HPLC-Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples. 2016 , 62, 1593-1601	24
965	Pragmatic medicine in solid cancer: a translational alternative to precision medicine. 2016 , 9, 1839-55	5
964	Maintaining High Level of Care at Satellite Sickle Cell Clinics. 2016 , 27, 280-292	7
963	Changes seen on computed tomography of the chest in mildly symptomatic adult patients with sickle cell disease. 2016 , 49, 214-219	5
962	Changes in Urine Microalbumin-to-Creatinine Ratio in Children with Sickle Cell Disease over Time. 2016 , 4, 106	6
961	Secondhand Smoke Is an Important Modifiable Risk Factor in Sickle Cell Disease: A Review of the Current Literature and Areas for Future Research. 2016 , 13,	7
960	Examination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia. 2016 , 11, e0153244	6
959	Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease. 2016 , 11, e0163013	8
958	Novel insights in the management of sickle cell disease in childhood. 2016 , 5, 25-34	19
957	Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease. 2017 , 9, e2017015	18

956	Blood Banking Principles and Practices. 2016 , 688-708	
955	New insights into sickle cell disease: mechanisms and investigational therapies. 2016 , 23, 224-32	24
954	Method-dependent Discrepancies in Fetal Hemoglobin Quantification in Patients With Hemoglobin S. 2016 , 38, 402-5	
953	Haematopoietic stem cell transplantation for sickle cell disease - current practice and new approaches. 2016 , 174, 515-25	36
952	Alloimmunisation rates of sickle cell disease patients in the United States differ from those in other geographical regions. 2016 , 26, 225-30	10
951	Gene Therapy for Haemoglobinopathies. 2016 , 1-8	
950	Red blood cell alloimmunization in transfused patients with bone marrow failure syndromes. 2016 , 56, 1314-9	3
949	Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. 2016 , 81, 742-52	26
948	Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines. 2016 , 173, 927-37	37
947	Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?. 2016 , 63, 844-7	10
946	Clinically-oriented proteomic investigation of sickle cell disease: Opportunities and challenges. 2016 , 10, 816-30	5
945	Treatment of dental complications in sickle cell disease. 2016 , 4, CD011633	6
944	The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges. 2016 , 7, 302-315	26
943	Clinical Manifestations and Treatment of Adult Sickle Cell Disease. 2016 , 285-318	4
942	Preventive Care Delivery to Young Children With Sickle Cell Disease. 2016 , 38, 294-300	7
941	mTOR Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease. 2016 , 174, 461-9	22
940	Sickle Cell Disease. 2016 , 245-258	
939	Prevalence of stroke in children admitted with sickle cell anaemia to Mulago Hospital. 2016 , 16, 175	16

938	Translating sickle cell guidelines into practice for primary care providers with Project ECHO. 2016 , 21, 33616	18
937	The Role of Dermal Matrices in Treating Inflammatory and Diabetic Wounds. 2016 , 138, 148S-157S	15
936	Genetic determinants and stroke in children with sickle cell disease. 2016 , 92, 602-608	
935	Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease. 2016 , 113, 9527-32	30
934	CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 10-2016. A 22-Year-Old Man with Sickle Cell Disease, Headache, and Difficulty Speaking. 2016 , 374, 1265-75	3
933	Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease. 2016 , 22, 207-211	74
932	Sickle Cell Crisis and You: A How-to Guide. 2016 , 67, 787-790	2
931	Genetic Factors Modifying Sickle Cell Disease Severity. 2016 , 371-397	3
930	Future Perspectives for the Treatment of Sickle Cell Anemia. 2016 , 399-429	4
929	Venous thromboembolism in adults with sickle cell disease: experience of a single centre in the UK. 2016 , 95, 227-32	10
928	Endothelin receptor antagonists in sickle cell disease: A promising new therapeutic approach. 2016 , 159, 15-19	10
927	Hematology in Africa. 2016 , 30, 457-75	10
926	Transcranial Doppler Screening Among Children and Adolescents With Sickle Cell Anemia. 2016 , 170, 550-6	34
925	Gene Therapy for Hemoglobinopathies: Tremendous Successes and Remaining Caveats. 2016 , 24, 668-70	16
924	Sickle Cell Disease in Africa and the Arabian Peninsula: Current Management and Challenges. 2016 , 339-370	
923	Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications. 2016 , 30, 591-608	59
922	Red Blood Cell Antibodies in Hematology/Oncology Patients: Interpretation of Immuno-hematologic Tests and Clinical Significance of Detected Antibodies. 2016 , 30, 635-51	29
921	Recent treatment guidelines for managing adult patients with sickle cell disease: challenges in access to care, social issues, and adherence. 2016 , 9, 541-52	22

920	La dr̄panocytose en France. 2016 , 2016, 61-66	1
919	Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. 2016 , 127, 820-8	84
918	Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. 2016 , 127, 839-48	105
917	Pediatric Therapeutic Apheresis: A Critical Appraisal of Evidence. 2016 , 30, 217-22	11
916	Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia. 2016 , 175, 331-338	22
915	Daily Pain, Physical Activity, and Home Fluid Intake in Pediatric Sickle Cell Disease. 2017 , 42, 335-344	9
914	Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. 2016 , 2016,	12
913	Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State. 2016 , 51, S31-8	20
912	Care Coordination for Children With Sickle Cell Disease: A Longitudinal Study of Parent Perspectives and Acute Care Utilization. 2016 , 51, S55-61	4
911	Determining Adherence to Quality Indicators in Sickle Cell Anemia Using Multiple Data Sources. 2016 , 51, S24-30	11
910	Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease. 2016 , 51, S69-77	49
909	Patient/Family Education for Newly Diagnosed Pediatric Oncology Patients. 2016 , 33, 422-431	40
908	Transfusion Therapy in Specific Clinical Situations. 2016 , 304-359	
907	Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults. 2016 ,	3
906	Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. 2016 , 2016,	2
905	Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease. 2016 , 25, 921-935	12
904	Hematopoietic Cell Transplantation for Sickle Cell Disease. 2016 , 853-868	
903	Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial. 2016 , 63, 98-104	24

902	Where do all the red blood cells (RBCs) go? Results of a survey of RBC use in England and North Wales in 2014. 2016 , 56, 139-45	56
901	Secondhand smoke is associated with more frequent hospitalizations in children with sickle cell disease. 2016 , 91, 313-7	8
900	A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. 2016 , 91, 1181-1184	22
899	Emergency Medicine Management of Sickle Cell Disease Complications: An Evidence-Based Update. 2016 , 51, 370-381	18
898	ATS Core Curriculum 2016: Part III. Pediatric Pulmonary Medicine. 2016 , 13, 955-66	2
897	Genetic determinants and stroke in children with sickle cell disease. 2016 , 92, 602-608	6
896	[Pulmonary complications of sickle cell disease in children]. 2016 , 23, 1094-1106	4
895	Bacteremia in Patients with Heterotaxy: A Review and Implications for Management. 2016 , 11, 537-547	14
894	Community Health Workers as Support for Sickle Cell Care. 2016 , 51, S87-98	37
893	Blood Components. 2016 , 337-353	
892	Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. 2016 , 8, 360ra134	286
891	Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. 2016 , 36, 1166-1172	6
890	Cerebral Blood Flow Measurement for Neurological Assessments: Functional Transcranial Doppler Ultrasound. 2016 , 1077-1096	0
889	Uncommon retinal vascular diseases. 2016 , 11, 453-473	
888	Transfusion Support: Indications, Efficacy, and Complications. 2016 , 687-696	
887	Quality of care in sickle cell disease: Cross-sectional study and development of a measure for adults reporting on ambulatory and emergency department care. 2016 , 95, e4528	25
886	Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. 2016 , CD008360	5
885	Effects of hydroxyurea treatment for patients with hemoglobin SC disease. 2016 , 91, 238-42	40

884	Palliative Care Teams as Advocates for Adults with Sickle Cell Disease. 2016 , 19, 195-201	4
883	Red Blood Cell Antigen Genotyping for Sickle Cell Disease, Thalassemia, and Other Transfusion Complications. 2016 , 30, 197-201	40
882	The Opioid Drug Epidemic and Sickle Cell Disease: Guilt by Association. 2016 , 17, 1793-1798	45
881	The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia. 2016 , 387, 2545-53	39
880	Treating hemoglobinopathies using gene-correction approaches: promises and challenges. 2016 , 135, 993-1010	12
879	Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. 2016 , 138,	57
878	Deoxygenation Reduces Sickle Cell Blood Flow at Arterial Oxygen Tension. 2016 , 110, 2751-2758	17
877	Headache and Facial Pain in Sickle Cell Disease. 2016 , 20, 20	9
876	Minireview: Prognostic factors and the response to hydroxyurea treatment in sickle cell disease. 2016 , 241, 730-6	9
875	Pattern of Lung Function Is Not Associated with Prior or Future Morbidity in Children with Sickle Cell Anemia. 2016 , 13, 1314-23	26
874	Neurologic and Head and Neck Manifestations of Sickle Cell Disease. 2016 , 30, 779-98	8
873	Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. 2016 , 56, 298-306	9
872	Stroke recurrence in adult sickle cell patients: it is time for action!. 2016 , 56, 1001-4	2
871	Preoperative blood transfusions for sickle cell disease. 2016 , 4, CD003149	14
870	Assessing the Immunogenic Response of a Single Center's Pneumococcal Vaccination Protocol in Sickle Cell Disease. 2016 , 38, e102-6	8
869	Chronic Pulmonary Complications of Sickle Cell Disease. 2016 , 149, 1313-24	29
868	A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. 2016 , 374, 625-35	96
867	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWITCH): a multicentre, open-label, phase 3, non-inferiority trial. 2016 , 387, 661-670	297

866	Proceedings of a Sickle Cell Disease Ontology workshop - Towards the first comprehensive ontology for Sickle Cell Disease. 2016 , 9, 23-9	9
865	Red cell storage age policy for patients with sickle cell disease: A survey of transfusion service directors in the United States. 2016 , 54, 158-62	3
864	Sickle Cell Disease and Stroke: Diagnosis and Management. 2016 , 16, 27	18
863	The European Hematology Association Roadmap for European Hematology Research: a consensus document. 2016 , 101, 115-208	46
862	Development of a New Adult Sickle Cell Disease Center Within an Academic Cancer Center: Impact on Hospital Utilization Patterns and Care Quality. 2016 , 3, 176-82	6
861	Preoperative Anemia: Evaluation and Treatment. 2016 , 34, 127-41	17
860	Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era. 2016 , 241, 749-54	17
859	Crises in Sickle Cell Disease. 2016 , 149, 1082-93	57
858	Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes over Two Years. 2016 , 25, 325-36	19
857	Psychometric Properties of the Psychosocial Assessment Tool-General in Adolescents and Young Adults With Sickle Cell Disease. 2016 , 41, 397-405	14
856	Inflammatory targets of therapy in sickle cell disease. 2016 , 167, 281-97	26
855	Overactive bladder in adults with sickle cell disease. 2016 , 35, 642-6	6
854	Exploring Transition to Self-Management Within the Culture of Sickle Cell Disease. 2017 , 28, 70-78	7
853	Sickle cell disease. 2017 , 390, 311-323	406
852	AAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain. 2017 , 18, 490-498	93
851	A Randomized Trial of Yoga for Children Hospitalized With Sickle Cell Vaso-Occlusive Crisis. 2017 , 53, 1026-1034	19
850	Older red cell units are associated with an increased incidence of infection in chronically transfused adults with sickle cell disease. 2017 , 56, 345-351	5
849	Genotyping Applications for Transplantation and Transfusion Management: The Emory Experience. 2017 , 141, 329-340	18

848	Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis. 2017 , 32, 1451-1456	44
847	A systematic review of the literature for severity predictors in children with sickle cell anemia. 2017 , 65, 86-94	18
846	Timely Care for Sickle Cell. 2017 , 43, 113-115	1
845	Validity of simple clinical and biological parameters as screening tool for sickle cell anemia for referral to tertiary center in highly resource constraints. 2017 , 31,	1
844	Transfusion Therapy in Children With Sickle Cell Disease. 2017 , 39, 126-132	8
843	Hydroxyurea for nontransfusion-dependent β -thalassemia: A systematic review and meta-analysis. 2017 , 10, 116-125	20
842	Clinical Hematologic. 244-249	
841	Sickle Cell Disease. 2017 , 376, 1561-1573	561
840	Sickle cell disease: Where are we now?. 2017 , 47, 26-34	1
839	A reappraisal of the mechanisms underlying the cardiac complications of sickle cell anemia. 2017 , 64, e26607	5
838	Hemoglobin and mean platelet volume predicts diffuse T1-MRI white matter volume decrease in sickle cell disease patients. 2017 , 15, 239-246	18
837	From total blood exchange to erythrocytapheresis and back to treat complications of sickle cell disease. 2017 , 57, 2277-2280	6
836	Transcranial Doppler screening for stroke risk in children with sickle cell disease: a systematic review. 2017 , 12, 580-588	11
835	Perioperative considerations for patients with sickle cell disease: a narrative review. 2017 , 64, 860-869	23
834	Sickle cell disease in the older adult. 2017 , 49, 1-9	33
833	Sickle cell disease: tipping the balance of genomic research to catalyse discoveries in Africa. 2017 , 389, 2355-2358	8
832	Changes in urine albumin to creatinine ratio with the initiation of hydroxyurea therapy among children and adolescents with sickle cell disease. 2017 , 64, e26665	10
831	Thalassemia Major and Priapism: A Case Report of an Adolescent. 2017 , 39, e336-e337	2

830	Utilizing a Novel Mobile Health "Selfie" Application to Improve Compliance to Iron Chelation in Pediatric Patients Receiving Chronic Transfusions. 2017 , 39, 223-229	17
829	Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. 2017 , 177, 620-629	39
828	Hydroxyurea inhibits parvovirus B19 replication in erythroid progenitor cells. 2017 , 136, 32-39	18
827	Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banks. 2017 , 102, 976-983	6
826	Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. 2017 , 129, 155-161	55
825	Discontinuation of Folic Acid Supplementation in Young Patients With Sickle Cell Anemia. 2017 , 39, 470-472	5
824	Sickle cell disease: a natural model of acute and chronic pain. 2017 , 158 Suppl 1, S79-S84	27
823	Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice. 2017 , 28, 2443-2458	35
822	How we manage iron overload in sickle cell patients. 2017 , 177, 703-716	42
821	Decline of Lung Function in Children with Sickle Cell Disease Is Not Associated with Restrictive Defects. 2017 , 14, 475-477	1
820	Managing the patient with haemoglobinopathy and multiple red cell antibodies. 2017 , 12, 51-61	1
819	Factors predictive of leg-ulcer healing in sickle cell disease: a multicentre, prospective cohort study. 2017 , 177, 206-211	13
818	UGT1A1 (TA) genotype is not the major risk factor of cholelithiasis in sickle cell disease children. 2017 , 98, 296-301	6
817	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. 2017 , 129, 1548-1556	230
816	Knowledge insufficient: the management of haemoglobin SC disease. 2017 , 176, 515-526	25
815	Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. 2017 , 48, e44-e71	178
814	Stany chorobowe związane z nadmiernym gromadzeniem żłaza oraz metody oznaczania zawartości żłaza w wřrobie. 2017 , 48, 308-315	1
813	Alloimmunisation and nephropathy in sickle cell disease patients in Jeddah, Saudi Arabia. 2017 , 12, 386-392	0

812	Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion. 2017 , 130, 2654-2663	30
811	Sickle cell disease and the eye. 2017 , 28, 623-628	17
810	Primer in Genetics and Genomics, Article 5-Further Defining the Concepts of Genotype and Phenotype and Exploring Genotype-Phenotype Associations. 2017 , 19, 576-585	1
809	A Diagnostic Approach to Stroke in Young Adults. 2017 , 19, 84	5
808	The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait. 2017 , 10, 1087-1094	29
807	Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. 2017 , 130, 2585-2593	63
806	Application of genomics for transfusion therapy in sickle cell anemia. 2017 , 67, 148-154	10
805	Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia. 2017 , 57, 2738-2746	26
804	Longitudinal Analysis of Echocardiographic Abnormalities in Children With Sickle Cell Disease. 2017 , 39, 500-505	4
803	Factors influencing utilization of hospital services by adult sickle cell disease patients: a systematic review. 2017 , 15, 765-808	12
802	Association of Guideline-Adherent Antibiotic Treatment With Readmission of Children With Sickle Cell Disease Hospitalized With Acute Chest Syndrome. 2017 , 171, 1090-1099	10
801	A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. 2017 , 92, 1333-1339	42
800	The role of policy in red blood cell storage and transfusion in children. 2017 , 82, 894-896	0
799	Autoimmune Liver Disease in Children with Sickle Cell Disease. 2017 , 189, 79-85.e2	16
798	Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease. 2017 , 34, 2007-2021	16
797	Human leukocyte antigen distribution and genomic ancestry in Brazilian patients with sickle cell disease. 2017 , 90, 211-218	3
796	Interventions for chronic kidney disease in people with sickle cell disease. 2017 , 7, CD012380	5
795	Prospective evaluation of chronic organ damage in adult sickle cell patients: A seven-year follow-up study. 2017 , 92, E584-E590	16

794	Use of anti-inflammatory analgesics in sickle-cell disease. 2017 , 42, 656-660	7
793	Interventions for treating intrahepatic cholestasis in people with sickle cell disease. 2017 , 7, CD010985	7
792	Evidence-Based Practice Standard Care for Acute Pain Management in Adults With Sickle Cell Disease in an Urgent Care Center. 2017 , 26, 108-115	6
791	Hydroxyurea: Analytical techniques and quantitative analysis. 2017 , 67, 135-142	10
790	Opportunities for model-based precision dosing in the treatment of sickle cell anemia. 2017 , 67, 143-147	4
789	Acute pain crisis in a patient with sickle cell disease undergoing ovarian stimulation for fertility preservation prior to curative stem cell transplantation: case report and literature review. 2017 , 34, 1445-1448 ⁹	
788	The Use of Cannabis by Patients with Sickle Cell Disease Increased the Frequency of Hospitalization due to Vaso-Occlusive Crises. 2017 , 2, 197-201	11
787	[Indirect causes of maternal deaths (except stroke, cardiovascular diseases and infections): Results from the French confidential enquiry into maternal deaths, 2010-2012]. 2017 , 45, S71-S80	0
786	Clinical Features of β Thalassemia and Sickle Cell Disease. 2017 , 1013, 1-26	4
785	Genetic Basis and Genetic Modifiers of β Thalassemia and Sickle Cell Disease. 2017 , 1013, 27-57	22
784	Sickle Mice Are Sensitive to Hypoxia/Ischemia-Induced Stroke but Respond to Tissue-Type Plasminogen Activator Treatment. 2017 , 48, 3347-3355	7
783	Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease. 2017 , 1013, 59-87	17
782	Technological Advances in Sickle Cell Disease. 2017 , 67, 102-103	4
781	Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study. 2017 , 64, e26689	20
780	Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome. 2017 , 20, 232-238	16
779	Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS [®] to ASCQ-MeSM. 2017 , 15, 117	29
778	Anti-Toxoplasma gondii antibodies in patients with beta-hemoglobinopathies: the first report in the Americas. 2017 , 10, 211	3
777	Sickle Cell Disease. 2017 , 2601-2615	

776	Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease. 2017 , 57, 2267-2276	12
775	The hepatocyte-specific HNF4 α miR-122 pathway contributes to iron overload-mediated hepatic inflammation. 2017 , 130, 1041-1051	36
774	Opioid prescription practices at discharge and 30-day returns in children with sickle cell disease and pain. 2017 , 64, e26319	4
773	Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort. 2017 , 92, 77-81	20
772	Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease. 2017 , 31, 145-154	9
771	Ten tips for managing critically ill patients with sickle cell disease. 2017 , 43, 80-82	2
770	Red blood cell exchange: 2015 American Society for Apheresis consensus conference on the management of patients with sickle cell disease. 2017 , 32, 342-367	23
769	Pediatric sickle cell disease: past successes and future challenges. 2017 , 81, 249-258	9
768	Intranasal fentanyl for initial treatment of vaso-occlusive crisis in sickle cell disease. 2017 , 64, e26332	20
767	Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes. 2017 , 112, 79-86	18
766	Attitudes of Primary Care Physicians Toward Sickle Cell Disease Care, Guidelines, and Comanaging Hydroxyurea With a Specialist. 2017 , 8, 37-40	10
765	Asthma Screening in Pediatric Sickle Cell Disease: A Clinic-Based Program Using Questionnaires and Spirometry. 2017 , 30, 232-238	4
764	Acute Chest Syndrome in Children with Sickle Cell Disease. 2017 , 30, 191-201	49
763	Anemia in Pregnancy: A Pragmatic Approach. 2017 , 72, 730-737	28
762	Of pools, oceans, and the Dead Sea. 2017 , 130, 2578-2579	2
761	Drepanocitosis: situación actual y perspectivas. 2017 , 34, 32-39	1
760	A 15-year-old boy with sickle cell disease, chest pain and respiratory distress. 2017 , 189, E1529-E1530	
759	Implementing a standard-of-care clinic for stroke prevention in children with sickle cell disease in Nigeria: a feasible strategy outside a clinical trial setting. 2017 , 1, 23-25	0

758	Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California. 2017 , 1, 1287-1295	35
757	Perioperative Management of Sickle Cell Disease. 2018 , 10, e2018032	20
756	Peripheral Mechanisms of Ischemic Myalgia. 2017 , 11, 419	21
755	Does Transcranial Direct Current Stimulation Combined with Peripheral Electrical Stimulation Have an Additive Effect in the Control of Hip Joint Osteonecrosis Pain Associated with Sickle Cell Disease? A Protocol for a One-Session Double Blind, Block-Randomized Clinical Trial. 2017 , 11, 633	4
754	Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country. 2017 , 2017, 3518402	4
753	Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project. 2017 , 2017, 4070547	30
752	Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. 2017 , 15, 136	52
751	A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring. 2017 , 2,	5
750	A Fatal Case of Immune Hyperhemolysis with Bone Marrow Necrosis in a Patient with Sickle Cell Disease. 2017 , 9, 6934	4
749	A prospective study of the association between sickle cell disease and hepatobiliary effects in Bahrain. 2017 , 10, 221-226	1
748	Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease. 2017 , 2017, 525-533	9
747	Rigorous and practical quality indicators in sickle cell disease care. 2017 , 2017, 418-422	3
746	3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology. 2017 , 109, 1-104	11
745	Nephrin as a biomarker of sickle cell glomerulopathy in Malawi. 2018 , 65, e26993	6
744	Effective screening leads to better outcomes in sickle cell disease. 2018 , 103, 628-630	2
743	Vascular access for red blood cell exchange. 2018 , 58 Suppl 1, 569-579	11
742	Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment. 2018 , 137, 191-200	11
741	Use of red blood cell exchange for treating acute complications of sickle cell disease. 2018 , 57, 23-26	9

740	Angiotensin receptor signaling in sickle cell anemia has a reno-protective effect on urine concentrating ability but results in sickle glomerulopathy. 2018 , 93, E177-E181	10
739	Stigma of Sickle Cell Disease: A Systematic Review. 2018 , 39, 675-686	39
738	Pediatric Pain. 2018 , 655-682	1
737	Automated RBC exchange compared to manual exchange transfusion for children with sickle cell disease is cost-effective and reduces iron overload. 2018 , 58, 1356-1362	13
736	Sickle cell disease: Classification of clinical complications and approaches to preventive and therapeutic management. 2018 , 68, 105-128	21
735	Vascular complications of sickle cell disease. 2018 , 68, 205-221	8
734	Sickle Cell Anemia and Its Phenotypes. 2018 , 19, 113-147	34
733	Sickle cell disease; An overview of the disease and its systemic effects. 2018 , 64, 283-289	10
732	Morts maternelles de causes indirectes (hors AVC, maladies cardiovasculaires et infections): résultats de l'ENCM, France 2010-2012. 2018 , 4, 99-111	
731	WITHDRAWN: Sickle cell disease; An overview of systemic and oral effects. 2018 ,	
730	Red blood cell antigen genotyping for haemoglobinopathies: considerations for thalassaemia and sickle cell disease. 2018 , 13, 238-243	3
729	Commentary: Heterogeneity of respiratory disease in children and young adults with sickle cell disease. 2018 , 73, 503	1
728	Clinical trial conduct in special populations and developing regions: An overview of the DOVE study in pediatric patients with sickle cell disease. 2018 , 64, 88-94	
727	Risk Factors for Development of Acute Chest Syndrome. 2018 , 39, 59-59	1
726	A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated With Achieving Optimal Hydroxyurea Therapy in Children With Sickle Cell Disease. 2018 , 40, 341-347	
725	Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease. 2018 , 24, 1554-1562	0
724	The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice. 2018 , 8, 6081	4
723	Red blood cell alloimmunization in sickle cell disease: assessment of transfusion protocols during two time periods. 2018 , 58, 1588-1596	8

722	Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline. 2018 , 58, 1555-1566	38
721	Modifying factors of the health belief model associated with missed clinic appointments among individuals with sickle cell disease. 2018 , 23, 683-691	8
720	Sickle cell disease. 2018 , 4, 18010	373
719	HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease. 2018 , 197, 177-185.e2	7
718	Describing Perceived Racial Bias Among Youth With Sickle Cell Disease. 2018 , 43, 779-788	16
717	Transfusion-transmitted malaria masquerading as sickle cell crisis with multisystem organ failure. 2018 , 58, 1550-1554	3
716	A Multidisciplinary Approach to Impact Acute Care Utilization in Sickle Cell Disease. 2018 , 33, 127-131	7
715	Neonatal screening improves sickle cell disease clinical outcome in Belgium. 2018 , 25, 57-63	7
714	Critical updates in the 7 edition of the American Society for Apheresis guidelines. 2018 , 33, 78-94	10
713	Behavioral and Pharmacological Adherence in Pediatric Sickle Cell Disease: Parent-Child Agreement and Family Factors Associated With Adherence. 2018 , 43, 31-39	5
712	Outcomes of Unrelated Donor Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease. 2018 , 24, 413-417	5
711	Use of the blood substitute HBOC-201 in critically ill patients during sickle crisis: a three-case series. 2018 , 58, 132-137	22
710	Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. 2018 , 69, 82-89	25
709	Family Functioning, Medical Self-Management, and Health Outcomes Among School-Aged Children With Sickle Cell Disease: A Mediation Model. 2018 , 43, 423-433	11
708	Daily Opioid Use Fluctuates as a Function of Pain, Catastrophizing, and Affect in Patients With Sickle Cell Disease: An Electronic Daily Diary Analysis. 2018 , 19, 46-56	28
707	Retinal microcirculation imaging in sickle cell disease patients. 2018 , 116, 1-5	5
706	HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease. 2018 , 24, 185-189	22
705	Special Populations with Anemia: Anemia in the Pediatric Patient. 2018 , 199-218	1

704	Management of Sickle Cell Anemia. 2018 , 219-236	
703	Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. 2018 , 111-136	1
702	Hydroxyurea therapy in UK children with sickle cell anaemia: A single-centre experience. 2018 , 65, e26833	11
701	State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease. 2018 , 20, 29-42	6
700	Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey. 2018 , 65, e26774	21
699	Current Non-HSCT Treatments for SCD. 2018 , 65-86	
698	Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease. 2018 , 83, 445-454	13
697	Indications for Allogeneic Hematopoietic Stem Cell Transplantation in Adults. 2018 , 83-109	2
696	Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. 2018 , 11, 45-55	13
695	Clinical and hematological profile in a newborn cohort with hemoglobin SC. 2018 , 94, 666-672	4
694	Stigma and Pain in Adolescents Hospitalized for Sickle Cell Vasoocclusive Pain Episodes. 2018 , 34, 438-444	20
693	Pediatric to adult care co-location transitional model for youth with sickle cell disease. 2018 , 93, E30-E32	12
692	Fetal haemoglobin induction in sickle cell disease. 2018 , 180, 189-200	34
691	Acute chest syndrome among children hospitalized with vaso-occlusive crisis: A nationwide study in the United States. 2018 , 65, e26885	13
690	Variations in pediatric emergency medicine physician practices for intravenous fluid management in children with sickle cell disease and vaso-occlusive pain: A single institution experience. 2018 , 65, e26742	6
689	Transfusion in Haemoglobinopathies: Review and recommendations for local blood banks and transfusion services in Oman. 2018 , 18, e3-e12	4
688	Hämoglobinopathien als Herausforderung der Migrantenmedizin. 2018 , 166, 968-976	1
687	Clinical and hematological profile in a newborn cohort with hemoglobin SC. 2018 , 94, 666-672	

686	Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease. 2018 , 2018, 8296139	19
685	Factors Associated With Mechanical Ventilation Use in Children With Sickle Cell Disease and Acute Chest Syndrome. 2018 , 19, 801-809	6
684	BMI, Psychosocial Correlates, Pain and Activities of Daily Living in Sickle Cell Disease Patients. 2018 , 3, e0019	2
683	The clinical impact of glucose-6-phosphate dehydrogenase deficiency in patients with sickle cell disease. 2018 , 25, 494-499	8
682	Hyperhemolysis Syndrome in Patients With Sickle Cell Disease. 2018 , 142, 1425-1427	13
681	Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms. 2018 , 8, 103	2
680	Hematologic Challenges in the Critically Ill: Obstetrics. 2018 , 199-213	
679	Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. 2018 , 35, 297-308	27
678	Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. 2019 , 66, e27588	3
677	An Update on the Basic and Clinical Science of Ketamine Analgesia. 2018 , 34, 1077-1088	8
676	Prescription audit in a paediatric sickle cell clinic in South-West Nigeria: A cross-sectional retrospective study. 2017 , 29, 285-289	1
675	Mouse Models of Pain in Sickle Cell Disease. 2018 , 85, e54	10
674	Evaluating Microalbuminuria in Children with Sickle Cell Disease: Review of the Literature. 2018 , 14, 739-744	
673	The need for care integration across hospital services for adults with sickle cell disease. 2018 , 26, 309-327	
672	Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature. 2018 , 18, 246	7
671	Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. 2018 , 183, 648-660	54
670	Effectiveness of Clinical Decision Support Based Intervention in the Improvement of Care for Adult Sickle Cell Disease Patients in Primary Care. 2018 , 31, 812-816	5
669	Vaso-occlusive crisis as a predictor of symptomatic avascular necrosis in children with sickle cell disease. 2018 , 65, e27435	3

668	The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease. 2018 , 93, E391-E395	27
667	Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and β -thalassemia. 2018 , 101, 798-803	12
666	How I treat the older adult with sickle cell disease. 2018 , 132, 1750-1760	14
665	How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders. 2018 , 132, 1770-1780	4
664	Red blood cell exchange in patients with sickle cell disease-indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB. 2018 , 58, 1965-1972	22
663	Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis. 2018 , 65, e27420	8
662	Measuring success: utility of biomarkers in sickle cell disease clinical trials and care. 2018 , 2018, 482-492	13
661	Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease. 2018 , 2, 575-585	4
660	Identification of patients with hemoglobin SS/ β -thalassemia disease and pain crises within electronic health records. 2018 , 2, 1172-1179	4
659	Impact of Intranasal Fentanyl in Nurse Initiated Protocols for Sickle Cell Vaso-occlusive Pain Episodes in a Pediatric Emergency Department. 2018 , 93, E205	7
658	Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series. 2018 , 32, 20-26	12
657	Stroke Prevalence in Children With Sickle Cell Disease in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. 2018 , 5, 2333794X18774970	11
656	Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. 2018 , 65, e27228	34
655	Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. 2018 , 55, 102-112	7
654	Stigma in adults with sickle cell disease and family members: Scale development and pilot study in the USA and Nigeria. 2018 , 9, 23-29	3
653	Generating evidence to inform an update of asthma clinical practice guidelines: Perspectives from the National Heart, Lung, and Blood Institute. 2018 , 142, 744-748	13
652	Profound underdosing of β -lactams in patients with sickle-cell disease. 2018 , 73, 3211-3212	1
651	Adapting medical guidelines to be patient-centered using a patient-driven process for individuals with sickle cell disease and their caregivers. 2018 , 18, 12	8

650	Systematic literature review and assessment of patient-reported outcome instruments in sickle cell disease. 2018 , 16, 99	13
649	Sickle Cell Disease. 2018 , 584-607.e5	1
648	genotype matching for transfusion support in sickle cell disease. 2018 , 132, 1198-1207	49
647	Oxygen-dependent flow of sickle trait blood as an in vitro therapeutic benchmark for sickle cell disease treatments. 2018 , 93, 1227-1235	11
646	Sickle Cell Disease: Bone, Joint, Muscle, and Motor Complications. 2018 , 37, 221-227	5
645	Comprehensive Infant Clinic for Sickle Cell Disease: Outcomes and Parental Perspective. 2018 , 32, 485-489	3
644	Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. 2018 , 8, CD012082	6
643	Outcomes of febrile events in pediatric patients with sickle cell anemia. 2018 , 65, e27379	4
642	Management of patients with sickle cell disease in oral surgery. Literature review and update. 2018 , 119, 493-497	4
641	Bedside ultrasound as a predictive tool for acute chest syndrome in sickle cell patients. 2018 , 36, 1855-1861	3
640	Technology use and preferences to support clinical practice guideline awareness and adherence in individuals with sickle cell disease. 2018 , 25, 976-988	7
639	Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. 2018 , 5, CD012349	9
638	The role of nitrite in muscle function, susceptibility to contraction injury, and fatigability in sickle cell mice. 2018 , 80, 70-81	5
637	Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study. 2018 , 93, 1411-1419	8
636	Quality of Evidence-Based Guidelines for Transfusion of Red Blood Cells and Plasma: A Systematic Review. 2018 ,	18
635	Red cell transfusion in paediatric patients with thalassaemia and sickle cell disease: Current status, challenges and perspectives. 2018 , 57, 347-357	10
634	Incomplete implementation of guideline-based stroke prevention therapy in sickle cell disease. 2018 , 93, E222-E224	
633	Transfusion Medicine in Pediatric Settings. 2018 , 103-118	

632	Challenges Facing Transfusion Practices. 2018 , 185-195	
631	Impact of Red Blood Cell Antigen Matching on Alloimmunization and Transfusion Complications in Patients with Sickle Cell Disease: A Systematic Review. 2019 , 33, 12-23	21
630	Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell Anemia. 2019 , 41, 56-63	7
629	Essentials of Hematology. 2019 , 217-239.e8	1
628	The Lung in Sickle Cell Disease. 2019 , 903-908.e2	
627	Ultrafast cell edge detection by line-scan time-stretch microscopy. 2019 , 12, e201800044	
626	Quality Metrics and Health Care Utilization for Adult Patients with Sickle Cell Disease. 2019 , 111, 54-61	4
625	Emerging disease-modifying therapies for sickle cell disease. 2019 , 104, 1710-1719	32
624	Metabolic impact of red blood cell exchange with rejuvenated red blood cells in sickle cell patients. 2019 , 59, 3102-3112	7
623	Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi. 2019 , 66, e27954	11
622	Sickle cell disease: a review for the internist. 2019 , 14, 1051-1064	13
621	National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017. 2019 , 28, 1246-1250	16
620	Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease. 2019 , 44, 1196-1204	3
619	Immunohaematology: the core of laboratory transfusion practice. 2019 , 29, 143-145	
618	Characterizing complication risk from multisite, intermittent transfusions for the treatment of sickle cell disease. 2019 , 66, e27921	1
617	A pilot test of the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) and the Jenerette Self-Care Assessment (J-SAT) Tools in adults with sickle cell disease. 2019 , 5, 85	2
616	A Growing Population of Older Adults with Sickle Cell Disease. 2019 , 35, 349-367	3
615	Survival and specific outcome of sickle cell disease patients after renal transplantation. 2019 , 187, 676-680	8

614	Anemia predicts lower white matter volume and cognitive performance in sickle and non-sickle cell anemia syndrome. 2019 , 94, 1055-1065	11
613	Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children. 2019 , 144,	17
612	[Digestives diseases associated to sickle cell anemia in Lubumbashi: epidemiological and clinical aspects]. 2019 , 33, 253	1
611	Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease. 2019 , 14, e0223991	6
610	Sensitivity and Specificity of Ultrawide-Field Fundus Photography for the Staging of Sickle Cell Retinopathy in Real-Life Practice at Varying Expertise Level. 2019 , 8,	4
609	Inpatient pain management in sickle cell disease. 2019 , 76, 1965-1971	4
608	Non-invasive urinary biomarkers of renal function in sickle cell disease: an overview. 2019 , 98, 2653-2660	2
607	Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism: A Prospective Cohort Study of 12 Patients. 2019 , 43, 296-299	10
606	Evaluation of a Non-Parenteral Opioid Analgesia Protocol for Acute Sickle Cell Pain Episodes in Children. 2019 , 8,	2
605	Editorial for Special Issue "Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies". 2019 , 5, 36	1
604	Hydroxycarbamide and white matter integrity in paediatric sickle cell disease. 2019 ,	
603	Hydroxycarbamide and white matter integrity in pediatric sickle cell disease: Commentary to accompany: Hydroxycarbamide treatment in children with sickle cell anaemia is associated with more intact white matter integrity: a quantitative MRI study. 2019 , 187, 141-143	
602	Burden of neurological and neurocognitive impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study. 2019 , 19, 381	5
601	T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?. 2019 , 12, 733-752	4
600	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. 2019 , 16, e17-e32	15
599	Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria. 2019 , 43, 188-192	12
598	Patterns of prescribing hydroxyurea for sickle cell disease patients from a central hospital, Saudi Arabia. 2019 , 11, 7860	1
597	Spontaneous breathing during extracorporeal membrane oxygenation treatment of sickle cell disease acute chest syndrome. 2019 , 28, 100924	1

596	Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease. 2019 , 8,	2
595	Evaluation of Outcomes and Quality of Care in Children with Sickle Cell Disease Diagnosed by Newborn Screening: A Real-World Nation-Wide Study in France. 2019 , 8,	8
594	Echocardiographic Screening of Cardiovascular Status in Pediatric Sickle Cell Disease. 2019 , 40, 1670-1678	3
593	Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy. 2019 , 94, 417-423	29
592	Home Oxygen Therapy for Children. An Official American Thoracic Society Clinical Practice Guideline. 2019 , 199, e5-e23	50
591	Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease. 2019 , 50, 266-273	22
590	Effectiveness of hydroxycarbamide in children with sickle cell disease - Analysis of dose-response metrics in a large birth cohort in a tertiary sickle cell centre. 2019 , 66, e27615	1
589	Developmental Stages and Clinical Conditions for Vascular Access in Pediatrics. 2019 , 171-179	
588	A brief review of common mathematical calculations in therapeutic apheresis. 2019 , 34, 607-612	4
587	Sickle Cell Disease. 2019 , 1279-1281	
586	The effects of hydroxycarbamide on the plasma proteome of children with sickle cell anaemia. 2019 , 186, 879-886	3
585	Current challenges in the management of patients with sickle cell disease - A report of the Italian experience. 2019 , 14, 120	12
584	Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy. 2019 , 66, e27816	7
583	Interval decline in hemoglobin A is associated with annual clinical event rate in sickle cell anemia patients receiving maintenance apheresis RBC exchange. 2019 , 59, 2622-2628	1
582	A Differential Approach to an Uncommon Case of Acute Anemia in a Child With Sickle Cell Disease. 2019 , 6, 2333794X19848674	3
581	Surgery for Moyamoya Disease in Children. 2019 , 34, 517-529	9
580	Hydroxyurea Treatment for Sickle Cell Anemia in Africa. 2019 , 41, 53-53	
579	Sickle cell disease: Clinical presentation and management of a global health challenge. 2019 , 37, 100580	22

578	Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. 2019 , 94, 871-879	35
577	Challenges to Family Management for Caregivers of Adolescent and Young Adult Survivors of Childhood Brain Tumors [Formula: see text]. 2019 , 36, 402-412	8
576	Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD. 2019 , 134, 579-590	14
575	Barriers and facilitators to care for individuals with sickle cell disease in central North Carolina: The emergency department providers' perspective. 2019 , 14, e0216414	12
574	Prevalence and Onset of Pediatric Sickle Cell Retinopathy. 2019 , 126, 1000-1006	7
573	Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of Literature. 2019 , 41, 624-626	1
572	Clinical management of rib fractures and methods for prevention of pulmonary complications: A review. 2019 , 50, 1159-1165	27
571	Pulmonary Hypertension in Children with Sickle Cell Disease: a Review of the Current Literature. 2019 , 7, 33-44	
570	Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. 2019 , 66, e27778	13
569	Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions. 2019 , 59, 2282-2291	16
568	Critical Care Management: Sepsis and Disseminated and Local Infections. 2019 , 253-274	1
567	Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain. 2019 , 94, 689-696	5
566	A Toll-like receptor 2 genetic variant modulates occurrence of bacterial infections in patients with sickle cell disease. 2019 , 185, 918-924	3
565	The National Heart, Lung, and Blood Institute Strategic Vision Implementation for Health Equity Research. 2019 , 29, 57-64	4
564	Red blood cell exchange techniques and methods. 2019 , 58, 132-135	7
563	Selecting red blood cell units to perform RBCX in patients with sickle cell disease. 2019 , 58, 142-146	4
562	Outcome After Exchange Transfusion for Central Retinal Vein Occlusion Associated With Extensive Capillary and Arteriolar Nonperfusion in a Patient With Hemoglobin SS Disease. 2019 , 137, 718-720	
561	Care of the Critically Ill Pediatric Sickle Cell Patient. 2019 , 71-93	

560	Developing a Problem-solving Intervention to Improve Self-Management and Transition Readiness in Adolescents with Sickle Cell Disease. 2019 , 46, 26-32	7
559	Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature. 2019 , 185, 743-751	11
558	Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia. 2019 , 133, 2436-2444	27
557	Sickle cell disease: Hemostatic and inflammatory changes, and their interrelation. 2019 , 493, 129-137	7
556	Sickle Cell Disease: Monitoring, Current Treatment, and Therapeutics Under Development. 2019 , 33, 355-371	9
555	Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. 2019 , 58, 1295-1307	6
554	Comorbidity of Glucose-6-Phosphate Dehydrogenase Deficiency and Sickle Cell Disease Exert Significant Effect on RBC Indices. 2019 , 2019, 3179173	6
553	Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease. 2019 , 66, e27740	7
552	Kidney biopsy findings in children with sickle cell disease: a Midwest Pediatric Nephrology Consortium study. 2019 , 34, 1435-1445	14
551	Catastrophic sickling crisis in patient undergoing cardiac transplantation with sickle cell trait. 2019 , 19, 2378-2382	4
550	Impact of Bariatric Surgery on Outcomes of Patients with Sickle Cell Disease: a Nationwide Inpatient Sample Analysis, 2004-2014. 2019 , 29, 1789-1796	4
549	Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action. 2019 , 66, e27657	10
548	Social media discussions provide new insight about perceptions of hydroxyurea in the sickle cell community. 2019 , 94, E134-E136	2
547	Heterotaxy. 2019 , 796-803.e3	1
546	TALEN-Mediated Gene Editing of in Human Hematopoietic Stem Cells Leads to Therapeutic Fetal Hemoglobin Induction. 2019 , 12, 175-183	31
545	Transfusion service knowledge and immunohaematological practices related to sickle cell disease and thalassemia. 2019 , 29, 185-192	4
544	Integration of neuropsychology services in a sickle cell clinic and subsequent healthcare use for pain crises. 2019 , 33, 1195-1211	6
543	Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease. 2019 , 3, 2816-2824	8

542	Sickle cell disease nephropathy: an update on risk factors and potential biomarkers in pediatric patients. 2019 , 13, 967-987	7
541	HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol. 2019 , 19, 354	2
540	Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results. 2019 , 3, 1476-1488	5
539	Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice. 2019 , 3, 1460-1475	8
538	Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. 2019 , 3, 3297-3306	4
537	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. 2019 , 3, 3867-3897	41
536	2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. 2019 , 3, 3945-3950	11
535	Effectiveness of Nurse Led Intervention on Health Related Quality of Life among Children with Sickle Cell Disease in Oman: A Pilot Study. 2019 , 2019, 6045214	2
534	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. 2019 , 3, 4002-4020	11
533	Identification of Clinical and Laboratory Parameters Associated with the Development of Acute Chest Syndrome during Vaso-Occlusive Episodes in Children with Sickle Cell Disease: A Preliminary Step before Assessing Specific and Early Treatment Strategies. 2019 , 8,	0
532	Longitudinal Trend in Emergency Department Reliance for Pain Among Sickle Cell Disease Patients in Wisconsin. 2019 , 41, e438-e442	5
531	Serum Immunoglobulin Levels in Children with Sickle Cell Disease: A Large Prospective Study. 2019 , 8,	2
530	Patient-controlled Analgesia For Vaso-Occlusive Crisis: A Cohort Study. 2019 , 35, 686-690	4
529	Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults. 2019 , 2019,	4
528	Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. 2019 , 2019,	2
527	The controversial role of red cell transfusions for sickle cell pain. 2019 , 26, 442-447	1
526	Improving the Care of Individuals With Sickle Cell Disease in the Emergency Department Using a Quality Improvement Framework: The Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS). 2019 , 41, 261-270	3
525	Treatment of dental complications in sickle cell disease. 2019 , 12, CD011633	1

524	CE: Understanding the Complications of Sickle Cell Disease. 2019 , 119, 26-35	10
523	Mechanisms of alloimmunization in sickle cell disease. 2019 , 26, 434-441	6
522	Health-related Quality of Life in Children With Sickle Cell Disease Undergoing Chronic Red Cell Transfusion Therapy. 2019 , 41, 307-312	7
521	EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. 2019 , 3, e208	7
520	The Role of Retinal Imaging in Sickle Cell Retinopathy: A Review. 2019 , 59, 71-82	2
519	Do chronic pain and comorbidities affect brain function in sickle cell patients? A systematic review of neuroimaging and treatment approaches. 2019 , 160, 1933-1945	1
518	Wide-field imaging of sickle retinopathy. 2019 , 5, 27	7
517	Preliminary exploration of secondhand smoke exposure in youth with Sickle Cell Disease: biochemical verification, pulmonary functioning, and health care utilization. 2019 , 24, 35-42	1
516	Hemoglobinopathies (Sickle Cell Disease and Thalassemia). 2019 , 595-601	2
515	Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease. 2019 , 184, 246-252	14
514	Paediatric immunisation and chemoprophylaxis in a Ugandan sickle cell disease clinic. 2019 , 55, 795-801	1
513	Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. 2019 , 184, 269-278	15
512	Hydroxyurea for Primary Stroke Prevention: The time draweth nigh. 2019 , 66, e27536	
511	Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease. 2019 , 16, 20-31	
510	Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting. 2019 , 94, 223-230	6
509	New Therapeutic Options for the Treatment of Sickle Cell Disease. 2019 , 11, e2019002	16
508	Hydroxyurea - An Essential Medicine for Sickle Cell Disease in Africa. 2019 , 380, 187-189	11
507	More efficient exchange of sickle red blood cells can be achieved by exchanging the densest red blood cells: An ex vivo proof of concept study. 2019 , 58, 100-106	1

506	Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. 2019 , 104, 919-928	22
505	Hemoglobin F as a predictor of health-related quality of life in children with sickle cell anemia. 2019 , 28, 473-479	7
504	Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. 2019 , 94, E27-E29	9
503	Pediatric residents' perceived barriers to opioid use in sickle cell disease pain management. 2019 , 66, e27535	7
502	Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. 2019 , 380, 121-131	103
501	Emerging pharmacotherapeutic approaches for the management of sickle cell disease. 2019 , 20, 173-186	11
500	Hemostatic Aspects of Sickle Cell Disease. 2019 , 819-842	
499	Clinical and Ophthalmic Factors Associated With the Severity of Sickle Cell Retinopathy. 2019 , 197, 105-113	12
498	Twelve tips for teaching a comprehensive disease-focused course with a global perspective: A sickle cell disease example. 2019 , 41, 275-281	0
497	Splenectomy to Optimize Hemoglobin S Control in Children With Sickle Cell Anemia on Chronic Transfusion Therapy for Stroke Prevention. 2019 , 41, 158-160	
496	Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis. 2020 , 24, 64-77	2
495	Predictive Analytics: Helping Guide the Implementation Research Agenda at the National Heart, Lung, and Blood Institute. 2019 , 14, 75-79	3
494	Evaluation of a clinical protocol using intranasal fentanyl for treatment of vaso-occlusive crisis in sickle cell patients in the emergency department. 2020 , 25, 293-299	7
493	Reversal of Severe Multiorgan Failure Associated With Sickle Cell Crisis Using Plasma Exchange: A Case Series. 2020 , 35, 140-148	6
492	Hemoglobinopathies (structural defects in hemoglobin). 2020 , 394-423	2
491	Retinal Thickness and Microvascular Changes in Children With Sickle Cell Disease Evaluated by Optical Coherence Tomography (OCT) and OCT Angiography. 2020 , 209, 88-98	21
490	Daily Associations between Child and Parent Psychological Factors and Home Opioid Use in Youth with Sickle Cell Disease. 2020 , 54, 61-66	4
489	Sickle cell disease subjects and mouse models have elevated nitrite and cGMP levels in blood compartments. 2020 , 94, 79-91	6

488	Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial. 2020 , 174, 113711	14
487	Perioperative care of children with sickle cell disease: A systematic review and clinical recommendations. 2020 , 95, 78-96	4
486	Hydroxyurea for ALL children with sickle cell anemia: What can we learn from Africa?. 2020 , 67, e28164	
485	Sickle cell disease in Germany: Results from a national registry. 2020 , 67, e28130	10
484	Haploidentical bone marrow transplantation in a patient with sickle cell disease and acute myeloid leukemia. 2020 , 24, e13641	1
483	Alloimmunization in Chronically Transfused Patients and Those With Malignancies. 2020 , 183-196	0
482	Transfusion support in patients with sickle cell disease. 2020 , 57, 39-50	5
481	Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use. 2020 , 33, 91-105	11
480	Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. 2020 , 11, 2040620720955000	7
479	How I Treat Acute and Persistent Sickle Cell Pain. 2020 , 12, e2020064	5
478	Osteomyelitis in sickle cell disease: You know it when you see it?. 2020 , 67, e28585	0
477	Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease. 2020 , 25, 229-240	
476	A meta-analysis of toxicities related to hydroxycarbamide dosing strategies. 2020 , 1, 235-238	
475	Novel hydration and nutritional strategies for sickle cell disease. 2020 , 1, 230-234	
474	Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia. 2020 , 10, 18982	1
473	Neuroimaging in Sickle Cell Disease: A Review. 2020 , 30, 725-735	3
472	COVID-19 and the pulmonary complications of sickle cell disease. 2020 , 1, 545-547	4
471	Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. 2020 , 21, 983	6

470	Procalcitonin to Reduce Antibiotic Exposure during Acute Chest Syndrome in Adult Patients with Sickle-Cell Disease. 2020 , 9,	2
469	Imunizaciones en niños, adolescentes y adultos inmunosuprimidos. 2020 , 31, 304-316	
468	Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?. 2020 , 4, 3457-3465	5
467	Stable renal function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation. 2020 , 67, e28568	3
466	Pain Experience, Physical Function, Pain Coping, and Catastrophizing in Children With Sickle Cell Disease Who Had Normal and Abnormal Sensory Patterns. 2020 , 60, 1079-1091	4
465	Pericapsular nerve group blockade for sickle cell disease vaso-occlusive crisis. 2020 , 66, 109932	2
464	Emotional distress among parent caregivers of adolescents with sickle cell disease: Association with patients and caregivers variables. 2021 , 26, 2851-2860	7
463	The Impact of Sickle Cell Anemia and Mental Health Diagnoses on Healthcare Use and Preventive Care among Children Enrolled in Medicaid, 2005-2012. 2020 , 224, 79-86.e2	
462	Transfusion support: Considerations in pediatric populations. 2020 , 57, 65-72	1
461	HLA-Matched Unrelated Donors for Patients with Sickle Cell Disease: Results of International Donor Searches. 2020 , 26, 2034-2039	1
460	Outpatient pain clinic and intranasal fentanyl to improve sickle cell disease outcomes. 2020 , 67, e28648	0
459	Pulmonary functions and associated risk factors among school teachers in a selected Nigerian population. 2020 , 1-7	0
458	Functional Connectivity Decreases with Metabolic Stress in Sickle Cell Disease. 2020 , 88, 995-1008	3
457	Warmed Saline for Vaso-occlusive Episodes in Sickle Cell Disease. 2020 , 44, 35-35	
456	Feasibility and preliminary outcomes of an integrated pediatric sickle cell disease and pulmonary care clinic for children with sickle cell disease. 2020 , 67, e28672	0
455	Sickle Cell Disease in the Democratic Republic of Congo: Assessing Physicians' Knowledge and Practices. 2020 , 5,	2
454	The molecular basis for the prothrombotic state in sickle cell disease. 2020 , 105, 2368-2379	12
453	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. 2020 , 4, 3804-3813	12

452	Evidence-based dental management in the new era of sickle cell disease: A scoping review. 2020 , 151, 668-677.e9	0
451	Practice patterns for neuroimaging and transfusion therapy for management of neurologic complications in sickle cell anemia: DISPLACE consortium. 2020 , 67, e28569	2
450	Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review. 2020 , 13, 361-377	7
449	Management of Osteomyelitis in Sickle Cell Disease: Review Article. 2020 , 4, e20.00002-10	4
448	The Effect of Use of Individualized Pain Plans in Sickle Cell Patients Presenting to the Emergency Department. 2020 , 76, S21-S27	3
447	Trends in Sickle Cell Disease-Related Mortality in the United States, 1979 to 2017. 2020 , 76, S28-S36	18
446	Association of Antibiotic Choice With Hospital Length of Stay and Risk Factors for Readmission in Patients With Sickle Cell Disease and Acute Chest Syndrome: An Observational Cohort Study. 2020 , 76, S37-S45	3
445	EDSC: Working to Improve Emergency Department Care of Individuals With Sickle Cell Disease. 2020 , 76, S80-S82	3
444	An Experimental-Computational Approach to Quantify Blood Rheology in Sickle Cell Disease. 2020 , 119, 2307-2315	3
443	Silent cerebral infarcts in patients with sickle cell disease: a systematic review and meta-analysis. 2020 , 18, 393	11
442	Integrating Datasets on Public Health and Clinical Aspects of Sickle Cell Disease for Effective Community-Based Research and Practice. 2020 , 8,	0
441	Outcomes related to intravenous fluid administration in sickle cell patients during vaso-occlusive crisis. 2020 , 99, 1217-1223	2
440	Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease. 2020 , 67, e28250	2
439	Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. 2020 , 105, e272-e275	9
438	The role of pain rehabilitation in an adolescent sickle cell disease population: a case series. 2020 , 37, 637-644	0
437	Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. 2020 , 136, 1402-1406	11
436	Fertility Concerns and Access to Care for Stem Cell Transplantation Candidates with Sickle Cell Disease. 2020 , 26, e192-e197	6
435	Effective use of hydroxyurea for sickle cell anemia in low-resource countries. 2020 , 27, 172-180	12

434	Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. 2020 ,	6
433	The role of MRA in pediatric sickle cell disease with normal transcranial Doppler imaging velocities. 2020 , 29, 104864	3
432	Optical coherence tomography (OCT) and OCT angiography allow early identification of sickle cell maculopathy in children and correlate it with systemic risk factors. 2020 , 258, 2551-2561	4
431	Comparison of pulse oximetry and earlobe blood gas with CO-oximetry in children with sickle cell disease: a retrospective review. 2020 , 4, e000690	2
430	Advances in Sickle Cell Disease Management. 2020 , 67, 57-71	3
429	Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. 2020 , 382, 2524-2533	27
428	[Sickle cell disease]. 2020 , 61, 754-758	2
427	Toxinology provides multidirectional and multidimensional opportunities: A personal perspective. 2020 , 6, 100039	1
426	American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. 2020 , 4, 2656-2701	53
425	Iron overload and periodontal status in patients with sickle cell anaemia: A case series. 2020 , 47, 668-675	3
424	Sickle cell disease induces resistance to cutaneous carcinogenesis. 2020 , 15, 66	2
423	Emerging therapies in sickle cell disease. 2020 , 190, 149-172	16
422	Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy. 2020 , 17, 589-600	21
421	A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease. 2020 , 24, 17	2
420	Preoperative transfusion versus no transfusion policy in sickle cell disease patients: a randomized trial. 2020 , 60 Suppl 1, S22-S27	1
419	Preoperative blood transfusions for sickle cell disease. 2020 , 7, CD003149	2
418	Pulmonary hypertension in children with hemolytic disorders. 2020 , 56, 101194	0
417	Red cell exchange for patients with sickle cell disease: an international survey of current practices. 2020 , 60, 1424-1433	5

416	Hemoglobin A and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy. 2020 , 67, e28499	0
415	Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies. 2020 , 374, 469-478	6
414	Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease?. 2020 , 35, 378-381	10
413	Impact of hereditary pancreatitis on patients and their families. 2020 , 29, 971-982	7
412	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. 2020 , 26, e94-e100	2
411	Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review. 2020 , 8, 38	22
410	Epidemiology and Predictors of all-cause 30-Day readmission in patients with sickle cell crisis. 2020 , 10, 2082	6
409	Association between hydroxycarbamide exposure and neurocognitive function in adolescents with sickle cell disease. 2020 , 189, 1192-1203	15
408	Cardiac causes of hypoxia in sickle cell disease. 2020 , 56, 101192	
407	Blood transfusions for treating acute chest syndrome in people with sickle cell disease. 2020 , 1, CD007843	2
406	Pediatric sickle cell disease. 2020 , 185-206	
405	Sickle Cell Retinopathy. 2020 , 154-158	
404	Inpatient Ordering of Home Hydroxyurea by Residents for Hospitalized Patients With Sickle Cell Disease. 2020 , 42, e38-e41	
403	Acupuncture for pediatric sickle cell pain management: A promising non-opioid therapy. 2020 , 49, 102314	2
402	Incorporating integrative medicine and patient preferences into a pilot interdisciplinary sickle cell wellness clinic. 2020 , 49, 102333	2
401	A Quality Initiative to Decrease Time to Antibiotics in Children with Sickle Cell Disease and Fever. 2020 , 5, e245	0
400	Review/overview of pain in sickle cell disease. 2020 , 49, 102327	7
399	Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). 2020 , 222, 236-239	3

398	Psychometric evaluation of the pediatric applied cognition scale in pediatric hematology/oncology. 2020 , 26, 1047-1064	2
397	A patient-centered medical home model for comprehensive sickle cell care in infants and young children. 2020 , 67, e28275	2
396	Sickle Chest Syndromes in Pregnancy. 2020 , 113-125	
395	American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. 2020 , 4, 1554-1588	90
394	Bleeding in patients with sickle cell disease: a population-based study. 2020 , 4, 793-802	2
393	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. 2020 , 4, 327-355	98
392	Spontaneous splenic rupture, mesenteric ischemia and spinal infarction after aortic repair for acute type A dissection in a patient with sickle cell trait. 2021 , 69, 560-563	
391	Risk factors for complications after abdominal surgery in children with sickle cell disease. 2021 , 56, 711-716	1
390	Imaging review of sickle cell disease for the emergency radiologist. 2021 , 28, 153-164	1
389	Caregiver Perception of Sickle Cell Disease Stigma in Ghana: An Ecological Approach. 2021 , 35, 84-90	1
388	Visual cortex changes in children with sickle cell disease and normal visual acuity: a multimodal magnetic resonance imaging study. 2021 , 192, 151-157	3
387	Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. 2021 , 96, 89-97	8
386	Delivering transformative action in paediatric pain: a Lancet Child & Adolescent Health Commission. 2021 , 5, 47-87	49
385	Predictors of dental complications post-dental treatment in patients with sickle cell disease. 2021 , 7, 11-19	2
384	Pulmonary Manifestations of Hematologic and Oncologic Diseases in Children. 2021 , 68, 61-80	2
383	An Interrupted Time Series Analysis of the Dissemination of a Sickle Cell Vaso-Occlusive Episode Treatment Algorithm and a Case Management Referral Form for Individuals With Sickle Cell Disease in the Emergency Department. 2021 , 47, 40-49.e1	1
382	Evaluation of knowledge and comfort with opioid prescribing among pediatric hematology/oncology fellows. 2021 , 68, e28786	1
381	Recommendation to reality: Closing the transcranial Doppler screening gap for children with sickle cell anemia. 2021 , 68, e28831	2

- 380 Sickle cell disease mice have cerebral oxidative stress and vascular and white matter abnormalities. **2021**, 86, 102493 2
- 379 Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. **2021**, 27, 167.e1-167.e12 1
- 378 Educational needs of patients and caregivers living with sickle cell disease results in development of web-based patient decision aid. **2021**, 77, 1432-1441
- 377 Nitric oxide and sickle cell disease-Is there a painful connection?. **2021**, 246, 332-341 1
- 376 Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine. **2021**, 109, 73-81 5
- 375 Management of Abdominal Surgery of Patients with Sickle-Cell Anaemia. **2021**, 10, 118-122
- 374 Hematology of Childhood and Adolescence. **2021**,
- 373 Vasculopathy and Vasculitis. **2021**, 217-273
- 372 Sickle Cell Disease in Children in Saudi Arabia: A Systematic Review. **2021**, 11, 97-102 1
- 371 Blood Disorders. **2021**, 641-664
- 370 Sickle Cell Nephropathy in Children. **2021**, 1-15
- 369 HSCT in Benign Hematological Disorders. **2021**, 115-163
- 368 Rare diseases. **2021**, 569-693
- 367 Mortality and Hospitalizations among Sickle Cell Disease Patients with End-Stage Kidney Disease Initiating Dialysis. **2020**, 51, 995-1003 0
- 366 MRI-based R2* mapping in patients with suspected or known iron overload. **2021**, 46, 2505-2515 0
- 365 Preoperative Therapy for Anemia. **2021**, 145-152
- 364 Therapeutic gene editing strategies using CRISPR-Cas9 for the Hemoglobinopathies. **2020**, 35, 115-134 2
- 363 Clinical Pathway for Vaso-Occlusive Pain Reduces Hospital Admissions.. **2022**, 44, 50-58

362	Hematopoietic-Stem-Cell-Targeted Gene-Addition and Gene-Editing Strategies for Hemoglobinopathies. 2021 , 28, 191-208	4
361	Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials. 2021 , 16, e0246700	2
360	Deep Learning Detection of Sea Fan Neovascularization From Ultra-Widefield Color Fundus Photographs of Patients With Sickle Cell Hemoglobinopathy. 2021 , 139, 206-213	4
359	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial (Preprint).	
358	Varied Age of First Presentation of Sickle Cell Disease: Case Presentations and Review. 2021 , 2021, 8895020	
357	Chronic organ injuries in children with sickle cell disease. 2021 , 106, 1535-1544	0
356	and Its Virulence Factors HO and Pneumolysin Are Potent Mediators of the Acute Chest Syndrome in Sickle Cell Disease. 2021 , 13,	3
355	Allogeneic stem cell transplantation with omidubicel in sickle cell disease. 2021 , 5, 843-852	3
354	Hydroxyurea: coming to conclusions on safety. 2021 , 137, 728-729	2
353	Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. 2021 , 194, 252-266	12
352	Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease. 2021 , 1	4
351	Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. 2021 , 68, e29008	1
350	Transcranial Doppler Screening in a Current Cohort of Children With Sickle Cell Anemia: Results From the DISPLACE Study. 2021 , 43, e1062-e1068	8
349	Total Hip Replacement in Sickle Cell Disease Patients with Avascular Necrosis of Head of Femur: A Retrospective Observational Study. 2021 , 55, 1225-1231	1
348	Improving access to healthcare for paediatric sickle cell disease patients: a qualitative study on healthcare professionals' views. 2021 , 21, 229	2
347	Nutritional perspectives on sickle cell disease in Africa: a systematic review. 2021 , 7, 9	0
346	Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. 2021 , 3, CD003427	1
345	Sickle Cell Disease and the Eye-Everything Old Is New Again. 2021 , 139, 337-338	

- 344 Opioids are not a major cause of death of patients with sickle cell disease. **2021**, 100, 1133-1138
- 343 Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. **2021**, 12, 636609 1
- 342 Transfusion Therapy in Specific Clinical Situations. **2021**, 257-324
- 341 Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease. **2021**, 16, 148 0
- 340 Sickle cell disease and ventricular myocardial strain: A systematic review. **2021**, 68, e28973 1
- 339 Impact of Ketamine in the Management of Painful Sickle Cell Disease Vaso-Occlusive Crisis.. **2022**, 57, 176-181
- 338 Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease. **2021**, 41, 101-119 3
- 337 Multifocal Bone Pain, Fevers, and an Enhancing Clavicular Lesion in an 11-year-old Liberian Boy. **2021**, 42, 147-150
- 336 Patient-controlled analgesia in sickle-cell disease painful vaso-occlusive crises: should we add ketamine to morphine?. **2021**, 87, 1146-1147
- 335 Improvement of SCD morbimortality in children: experience in a remote area of an African country. **2021**, 21, 294 3
- 334 Patient Perspectives of Sickle Cell Management in the Emergency Department. **2021**, 44, 160-174 0
- 333 Anti-DNA Virus Agents. 1-41
- 332 Therapeutic Strategies for the Treatment of Sickle Cell Disease. 1-31 1
- 331 Digital behavioural interventions for people with sickle cell disease. **2021**, 2021, 4
- 330 COVID-19 Mortality in a Pediatric Patient with Hemoglobin SC Disease and Alpha-Thalassemia Trait. **2021**, 2021, 6617362 0
- 329 Dissemination of Evidence-Based Recommendations for Sickle Cell Disease to Primary Care and Emergency Department Providers in North Carolina: A Cost Benefit Analysis. **2021**, 8, 18-28 1
- 328 Genetic therapies for the first molecular disease. **2021**, 131, 4
- 327 Electronic Health Record-Embedded Individualized Pain Plans for Emergency Department Treatment of Vaso-occlusive Episodes in Adults With Sickle Cell Disease: Protocol for a Preimplementation and Postimplementation Study. **2021**, 10, e24818 1

326	Red cell transfusion and alloimmunization in sickle cell disease. 2021 , 106, 1805-1815	6
325	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. 2021 , 10, e27650	2
324	Screening for new red blood cell alloantibodies after transfusion in patients with sickle cell disease. 2021 , 61, 2255-2264	1
323	Multifocal Osteonecrosis in a 3-Year-Old Child With Sickle Beta Plus Thalassemia. 2021 ,	1
322	Cardiovascular benefits of a home-based exercise program in patients with sickle cell disease. 2021 , 16, e0250128	0
321	[Newborn screening for sickle cell disease in France]. 2021 , 37, 482-490	0
320	Artificial intelligence for improving sickle cell retinopathy diagnosis and management. 2021 , 35, 2675-2684	1
319	Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease. 2021 ,	
318	Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease. 2021 , 8971900211026644	1
317	Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. 2021 , 66, 629338	1
316	Inaccurate Glucose Sensor Values After Hydroxyurea Administration. 2021 , 23, 443-451	4
315	Innovative Treatments for Rare Anemias. 2021 , 5, e576	0
314	A systems pharmacology model for gene therapy in sickle cell disease. 2021 , 10, 696-708	
313	Antigen matching for transfusion support in Brazilian female patients with sickle cell disease to reduce RBC alloimmunization. 2021 , 61, 2458-2467	1
312	Research in Sickle Cell Disease: From Bedside to Bench to Bedside. 2021 , 5, e584	5
311	Commonly used agent for acute pain management of sickle cell anemia in Saudi Emergency Department: A narrative review. 2021 , 29, 487-496	0
310	Transcranial color-coded duplex sonography reliably identifies intracranial vasculopathy in adult patients with sickle cell disease. 2021 , 96, 961-967	1
309	The EHA Research Roadmap: Anemias. 2021 , 5, e607	2

308	Biomarkers for the central nervous system complications of sickle cell disease: are we there yet?. 2021 , 15, e2100026	
307	Gene therapy for sickle cell disease: moving from the bench to the bedside. 2021 , 138, 932-941	8
306	The different facets of sickle cell disease-related pulmonary hypertension. 2021 , 27, 319-328	1
305	Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood. 2021 , 195, 256-266	10
304	Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. 2021 , 96, 1223-1231	6
303	Antibiotics to modify sickle cell disease vaso-occlusive crisis?. 2021 , 50, 100867	1
302	Health services use by children identified as heterozygous hemoglobinopathy mutation carriers via newborn screening. 2021 , 21, 296	
301	Do We Store Packed Red Blood Cells under "Quasi-Diabetic" Conditions?. 2021 , 11,	0
300	Provider Attitudes, Preferences, and Practices Regarding Sexual and Reproductive Health for Adolescents and Young Adults With Sickle Cell Disease. 2021 , 69, 970-975	1
299	Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database. 2021 , 16, e0253986	4
298	Therapeutic approach to pediatric patients with acute chest syndrome: national multicenter survey of non invasive ventilation (NIV) and transfusion. 2021 , 28, 559-566	
297	A non-injected opioid analgesia protocol for acute pain crisis in adolescents and adults with sickle cell disease.. 2022 , 16, 179-190	
296	Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. 2021 , 96, 1396-1406	7
295	How to Facilitate Decision-Making for Hematopoietic Stem Cell Transplantation in Patients With Hemoglobinopathies. The Perspectives of Healthcare Professionals. 2021 , 9, 690309	1
294	Identified barriers and facilitators to stroke risk screening in children with sickle cell anemia: results from the DISPLACE consortium. 2021 , 2, 87	0
293	Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project. 2021 , 195, e160-e164	
292	Efficient Clinical Counseling for Sickle Cell Disease. 2021 , 113, 382-387	
291	Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol). 2021 , 11, e047949	2

- 290 Neuroprotection: further evidence for the early and universal use of hydroxyurea in children with sickle cell disease. **2021**, 195, 158-159
- 289 Diagnostic and Treatment Update on Sickle Cell Retinopathy. **2021**, 6, 201-216
- 288 Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence. **2021**, 22, e531-e539
- 287 Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011-2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome. **2021**, 10, 0
- 286 Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy. **2021**, 5, 4406-4412 2
- 285 American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. **2021**, 5, 3668-3689 4
- 284 Engaging the Sickle Cell Community in Participatory Research. **2021**, 21, 51-53
- 283 Biopsychosocial Predictors of Quality of Life in Paediatric Patients With Sickle Cell Disease. **2021**, 12, 681137 2
- 282 A Case Series of Kawasaki Disease in Children With Sickle Cell Disease. **2021**,
- 281 Drpanocytose : les spificitš dātteinte dōrgane chez lānfant. **2021**, 2, 388-388
- 280 How I approach disease-modifying therapy in children with sickle cell disease in an era of novel therapies. **2021**, 68, e29363 1
- 279 An Immersive Virtual Reality Curriculum for Pediatric Hematology Clinicians on Shared Decision-making for Hydroxyurea in Sickle Cell Anemia.. **2022**, 44, e799-e803 1
- 278 One Small Step for Sickle Cell Disease: Many More to Go. **2021**, 174, 1313-1314
- 277 Sickle Cell Disease-Induced Pulmonary Hypertension: A Review of Pathophysiology, Management, and Current Literature.. **2021**, 9, 57-63 0
- 276 Racial and Ethnic Disparities in Discharge Opioid Prescribing From a Hospital Medicine Service. **2021**, 16, 589-595 1
- 275 Sickle cell disease in sub-Saharan Africa: transferable strategies for prevention and care. **2021**, 8, e744-e755 2
- 274 Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort. **2021**, 92, 102612 0
- 273 Anesthesia in Pediatric Otolaryngology. **2021**, 15-45 0

272	Sickle cell disease. 2021 , 689-693	
271	Blood Components. 2021 , 445-462	
270	Sickle Cell Disease. 2021 , 267-270	
269	Hemostatic alteration in sickle cell disease: Pathophysiology of the hypercoagulable State. 2021 , 6, 1	
268	Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. 2021 , 12, 686	17
267	Cerebral Blood Flow Measurement for Neurological Assessments: Functional Transcranial Doppler Ultrasound. 2015 , 1-20	1
266	Prognostic Value of Hyponatremia During Acute Painful Episodes in Sickle Cell Disease. 2020 , 133, e465-e482	0
265	Prise en charge pratique des complications aiguës de la drpanocytose chez l'enfant. 2018 , 1, 237-248	2
264	Paracentral Acute Middle Maculopathy as a Presenting Sign of CRAO in Sickle Cell Disease Treated with Tissue Plasminogen Activator. 2020 ,	1
263	Surgical and Medical Perioperative Management of Sickle Cell Retinopathy: A Literature Review. 2020 , 60, 77-87	1
262	The factors influencing utilization of hospital services by adult sickle cell disease patients: a systematic review protocol. 2015 , 13, 18-29	2
261	A predictable but life-threatening complication of hydroxyurea in a patient with sickle cell anaemia: an experience learned from a Jehovah's Witness. 2015 , 2015,	0
260	Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability. 2020 , 10, e038685	4
259	Mechanisms of pain in sickle cell disease. 2021 , 15, 213-220	4
258	Optimizing hydroxyurea therapy for sickle cell anemia. 2015 , 2015, 436-443	9
257	Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management. 2019 , 2019, 351-358	9
256	Sickle cell disease: a comprehensive program of care from birth. 2019 , 2019, 490-495	8
255	Optimal disease management and health monitoring in adults with sickle cell disease. 2019 , 2019, 505-512	4

254	Blood Cell Disorders and the Nervous System. 2020 , 26, 659-674	1
253	Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings. 2018 , 7,	2
252	Prostacyclin, thromboxane and glomerular filtration rate are abnormal in sickle cell pregnancy. 2017 , 12, e0184345	2
251	Lessons Learned from Building a Pediatric-to-Adult Sickle Cell Transition Program. 2019 , 112, 190-197	11
250	Sickle Cell Disease with Cyanotic Congenital Heart Disease: Long-Term Outcomes in 5 Children. 2016 , 43, 509-513	1
249	Analysis of Current Status of Chronic Red Blood Cell Transfusion. 2016 , 27, 229-236	5
248	A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study. 2019 , 7, e13452	10
247	Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach. 2020 , 8, e14884	20
246	Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study. 2020 , 9, e16319	6
245	Expanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia. 2016 , 5, e185	9
244	Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study. 2019 , 6, 106-117	7
243	Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study. 2020 , 7, 94-101	4
242	Sickle cell disease: Status with particular reference to India. 2016 , 143, 675-677	5
241	World Sickle Cell Day 2016 : A time for appraisal. 2016 , 143, 678-681	4
240	Therapeutic advances in sickle cell disease in the last decade. 2017 , 145, 708-712	2
239	Successful pulmonary thromboendarterectomy in a patient with sickle cell disease and associated resolution of a leg ulcer. 2018 , 35, 73-77	1
238	The Lived Experience of Parents of Children with Sickle Cell Disease: A Qualitative Study. 2017 , 07, 1348-1364	5
237	A Multidisciplinary Educational Approach for Children With Chronic Illness: An Intervention Case Study. 2020 , 1, 8-21	1

236	Immunization Adherence in Children With Sickle Cell Disease: A Single-Institution Experience. 2020 , 25, 39-46	3
235	. 2017 , 109, 1-76	119
234	Biopsychosocial factors related to transition among adolescents and young adults with sickle cell disease: A systematic review. 2021 , 167, 103498	0
233	Impact of sickle cell disease on postoperative outcomes following total hip arthroplasty. 2021 , 11207000211052224	
232	Commentary on "Primary Care Providers' Comfort Levels in Caring for Patients With Sickle Cell Disease". 2015 , 108, 537-8	1
231	History of Sickle Cell Anemia. 2016 , 1-17	
230	Epidemiology of Pulmonary Hypertension: From Quaternary Referral Centre to the Community. 2016 , 63-79	
229	Sickle Cell Disease: Management of Complications. 2016 , 75-87	
228	Implementation of Indigenous Electronic Medical Record System to Facilitate Care of Sickle Cell Disease Patients in Chhattisgarh. 2016 , 10, LC01-6	2
227	Sickle Cell Nephropathy. 2016 , 556-559	
226	Sickle Cell Disease: Prevention of Complications. 2016 , 63-73	
225	Therapeutic Apheresis in Hematologic Disorders: When and Why?. 2016 , 707-718	
224	Allogeneic Hematopoietic Cell Transplant in Sickle Cell Disease. 2016 , 89-96	
223	Hematological Problems in Pediatric Surgery. 2016 , 1-23	
222	Sickle Cell Disease. 2016 , 1-15	
221	Treatment and Management of Late Complications in Hereditary Hemolytic Anemia. 2016 , 23, 1-7	1
220	Combination of Exchange Transfusion Treatment and Hydroxyurea Cause Beneficial Changes to Laboratory Parameters and Clinical Outcome in Patients with Sickle Cell Disease/Thalassemia Compared with Hydroxyurea or Exchange Transfusion Alone. 2016 , 2,	2
219	Fever in an Adult with Sickle Cell Disease: To Treat or Not to Treat? A Case of Multi-Organ Failure. 2016 , 3,	

- 218 Implementation of Evidence-Based Care in the Sickle Cell and Hemophilia Patient Population. **2017**, 277-295
- 217 Hematologic Disorders of the Eye. **2017**, 295-325
- 216 Sickle Cell Disease. **2017**, 135-161
- 215 Long-Term Effects of Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. **2018**, 235-249
- 214 The Ethics of Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. **2018**, 199-219
- 213 Hyperhemolysis Syndrome in a Pregnant Woman with Sickle Cell Anemia. **2018**, 155-161
- 212 Therapeutic Red Cell Exchange Transfusion as an Adjuvant Therapy for Management of Sickle Cell Crisis in Adults. **2018**, 22, 457-459
- 211 Uncommon Cardiac Diseases. **2018**, 426-472
- 210 Sickle Cell Disease and Anesthesia Management in Laboring Women. **2018**, 529-534
- 209 Optimizing Hemoglobin S Percentage for Pediatric Sickle Cell Disease Patients Chronically Transfused with Red Cell Exchange. **2018**, 3,
- 208 Anemia de células falciformes en pediatría: Revisión de la literatura. **2018**, 20, 374-382
- 207 Anemia at the Extremes of Life: Congenital Hemolytic Anemia. **2019**, 95-135
- 206 Les grandes déclinaires des maladies chroniques. **2019**, 233-255
- 205 The role of red cell genotyping in transfusion medicine. **2019**, 31, 49-52 11
- 204 A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study (Preprint). 1
- 203 It Runs in the Family 2019, 315-332
- 202 Sickle cell disease complications: prevalence and resource utilization. 2
- 201 Diagnosis of hemoglobinopathy and β -thalassemia by 21-Tesla Fourier transform ion cyclotron resonance mass spectrometry. **2019**, 7, S239 2

- 200 Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study (Preprint). 1
- 199 High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study. **2019**, 6, 174-184 2
- 198 Sickle Cell Disease. **2020**, 227-231
- 197 Important Differences in Hematology Results and Hematological Diseases. **2020**, 121-137
- 196 Syndrome thoracique aigu. **2020**, 101-108
- 195 L-Selectin P213S and Integrin Alpha 2 C807T Genetic Polymorphisms in Pediatric Sickle Cell Disease Patients. **2020**, 42, e707-e711 2
- 194 Predictors of musculoskeletal manifestations in paediatric patients presenting with sickle cell disease at a tertiary teaching hospital in Lusaka, Zambia. **2020**, 1, 175-181
- 193 Sickle Cell Disease. **2021**, 65-89
- 192 A Complicated Case of Vaccine Refusal. **2020**, 146,
- 191 Altered mental status as a presentation of rhabdomyolysis in a patient with sickle cell anemia. **2021**, e29386
- 190 Variable Practice Patterns for Management of Sickle Cell Retinopathy. **2021**, 5, 715-717 2
- 189 Electronic Health Record Embedded Individualized Pain Plans for Emergency Department Treatment of Vaso-occlusive Episodes in Adults With Sickle Cell Disease: Protocol for a Preimplementation and Postimplementation Study (Preprint).
- 188 Optimizing the management of chronic pain in sickle cell disease. **2020**, 2020, 562-569 5
- 187 Assessing the atria in pediatric sickle cell disease: Beyond the dilation. **2021**, 38, 189-196
- 186 HSCT in Benign Hematological Disorders. **2021**, 1-49
- 185 Association between inflammatory molecules, nitric oxide metabolites and leg ulcers in individuals with sickle cell anemia. **2020**,
- 184 Health-Related Quality of Life of Children and Adolescents with Sickle Cell Disease in the Middle East and North Africa Region: A systematic review. **2020**, 20, e280-e289 1
- 183 Hematology and Oncology. **2020**, 289-308

182 Patient with Sickle Cell Disease. **2020**, 323-339

181 Traitement par hydroxyurè. **2020**, 203-209

180 Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. **2020**, 123-134 1

179 Hematological Problems in Pediatric Surgery. **2020**, 387-409

178 Non-Malignant Diseases Requiring Stem Cell Transplantation. **2020**, 115-122

177 Sickle Cell Retinopathy. **2020**, 147-156

176 Sickle Cell Disease in the Adolescent Female. **2020**, 217-225

175 The Liver in Sickle Cell Disease. **2021**, 72, 5-10 0

174 Predictors of musculoskeletal manifestations in paediatric patients presenting with sickle cell disease at a tertiary teaching hospital in Lusaka, Zambia. **2020**, 1, 175-181

173 Cas9-AAV6 Gene Correction of Beta-Globin in Autologous HSCs Improves Sickle Cell Disease Erythropoiesis in Mice.

172 Implementation of a learning healthcare system for sickle cell disease. **2020**, 3, 349-359 2

171 The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease. **2020**, 26, 1412-1422 0

170 Preoperative anaemia in surgical patients: Intravenous iron and erythropoiesis-stimulating agents (ESAs) to the rescue. **2020**, 1,

169 Complications of Central Venous Access Devices in Patients With Sickle Cell Disease and Thalassemia Major. **2021**, 43, e655-e660 2

168 Updated Mechanisms of Sickle Cell Disease-Associated Chronic pain. **2015**, 2, 8-17 15

167 Mortal quintet of sickle cell diseases. **2015**, 8, 11442-8 2

166 Genome editing and stem cell therapy pave the path for new treatment of sickle-cell disease. **2015**, 2, 22

165 Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease. **2020**, 11, 873-877

- 164 Prevalence of Sickle Cell Disease Among Anaemic Children Attending Mbeya Referral Hospital in Southern Tanzania. **2018**, 2, 142-146
- 163 JMM Profile: sugar-coated captain of the men of death. **2021**, 70, 1
- 162 Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA. **2021**, 11, e050880 1
- 161 Non-Mydriatic Ultra-Widefield Fundus Photography in a Hematology Clinic Shows Utility for Screening of Sickle Cell Retinopathy. **2021**, 1
- 160 Evaluation of Stillbirth Among Pregnant People With Sickle Cell Trait. **2021**, 4, e2134274 1
- 159 Nationwide retrospective study of critically ill adults with sickle cell disease in France. **2021**, 11, 23132 1
- 158 Anesthetic Management of Moyamoya Syndrome Secondary to Sickle Cell Anemia.
- 157 Acute Chest Syndrome in Children with Sickle Cell Disease: Current Perspectives on Pathogenesis and Treatment. 42-51
- 156 Sickle Cell Disease. **2018**,
- 155 Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease. **2020**, 11, 873-877 0
- 154 Evolving Strategies in the Management of Sickle Cell Disease in the 21st Century and the Role of the Pediatrician.. **2022**, 51, e34-e39
- 153 Identifying and Treating Severe Bone Marrow Necrosis and Fat Embolism Syndrome in Pediatric Patients With Sickle Cell Disease: A Case Report.. **2022**, 1
- 152 Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis and management.. **2022**, 1
- 151 Current Knowledge and Awareness of Dengue Fever among Students of Government College University Faisalabad. **2022**, 3, 060-064
- 150 Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center.. **2022**, 11, 0
- 149 Can galectin-3 be used to predict the severity of vasoocclusive crisis in patients with sickle cell anaemia?. **2022**, 9,
- 148 A Vascular Necrosis of Femoral Head in Sickle Cell Anemia.
- 147 Outcome of Hydroxyurea Use in SCD and Evaluation of Patients' Perception and Experience in Nigeria.. **2022**, 13, 826132 0

146	Risk factors for Venous Thromboembolism and clinical outcomes in adults with sickle cell disease. 2022 , 6, 100101	0
145	Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy.. 2022 , 9, 832154	1
144	Accuracy of transcranial Doppler in detecting intracranial stenosis in patients with sickle cell anemia when compared to magnetic resonance angiography.. 2022 ,	1
143	Barriers and Facilitators to Chronic Red Cell Transfusion Therapy in Pediatric Sickle Cell Anemia. 275275302110738	
142	Cardiac complications of Sickle Cell Disease in pediatric patients: A case report and contemporary literature review. 2022 , 101517	
141	Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.. 2022 , 54, 683-693	0
140	Nursing Education for the Acute Care Nurse on Pain Mechanisms of Sickle Cell Disease.. 2022 , 53, 137-144	
139	Demand-only patient-controlled analgesia for treatment of acute vaso-occlusive pain in sickle cell disease.. 2022 , e29665	1
138	Knowledge and Awareness of Sickle Cell Anemia: Cross Sectional Study among the General Population in Saudi Arabia. 69-74	
137	Moving Toward a Multimodal Analgesic Regimen for Acute Sickle Cell Pain with Non-Opioid Analgesic Adjuncts: A Narrative Review.. 2022 , 15, 879-894	0
136	Use of Person-Centered Language Among Scientific Research Focused on Sickle Cell Disease.. 2022 ,	1
135	Advances in the diagnosis and treatment of sickle cell disease.. 2022 , 15, 20	4
134	Adjuvant low-dose ketamine for paediatric and young adult sickle cell vaso-occlusive episodes in the emergency department.. 2022 ,	0
133	Adaptive Functioning in Children and Adolescents With Sickle Cell Disease.. 2022 ,	0
132	Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.. 2022 , e29607	0
131	Bridging the implementation gap in medication adherence. If you build it, will they come?. 2021 ,	1
130	System's failure: Poor adherence to guidelines for children with sickle cell disease. 2021 , e29471	
129	Stigma and quality of life in adults with sickle cell disease in Jamaica and the United States.. 2021 , 1-15	

128	Indications for transfusion in the management of sickle cell disease. 2021 , 2021, 696-703	0
127	Early testicular maturation is sensitive to depletion of spermatogonial pool in sickle cell disease. 2021 ,	2
126	Neurocognitive functioning in preschool children with sickle cell disease.. 2021 , e29531	2
125	Treatment dilemmas: strategies for priapism, chronic leg ulcer disease, and pulmonary hypertension in sickle cell disease. 2021 , 2021, 411-417	1
124	US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity.. 2022 , e29679	1
123	Strategies to increase access to basic sickle cell disease care in low- and middle-income countries.. 2022 , 1-12	0
122	How Would You Treat This Patient With Acute and Chronic Pain From Sickle Cell Disease? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.. 2022 ,	
121	Preventing antibody positive delayed hemolytic transfusion reactions in sickle cell disease: Lessons learned from a case.. 2022 ,	
120	Hematology. 2022 , 263-318	
119	Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial. NIH.. 2022 ,	0
118	Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.. 2022 , 17, e0267448	0
117	Accuracy of online medical information: the case of social media in sickle cell disease. 1-9	0
116	In-Depth Immunological Typization of Children with Sickle Cell Disease: A Preliminary Insight into Its Plausible Correlation with Clinical Course and Hydroxyurea Therapy. 2022 , 11, 3037	0
115	Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease. 2022 , 11, 3160	
114	Sickle cell disease in children: an update of the evidence for WHO guideline development. archdischild-2021-323633	
113	Complications lithiasiques chez les patients drpanocytaires. 2022 ,	
112	Longitudinal Study of Glomerular Hyperfiltration in Adults with Sickle Cell Anemia: A Multicenter Pooled Analysis.	0
111	Predictors of Recurrent Acute Chest Syndrome in Pediatric Sickle Cell Disease: A Retrospective Case-Control Study. 2022 , 9, 894	

- 110 Detection and Management of Cerebral Vasculopathy.
- 109 Considerations for Selecting Cognitive Endpoints and Psychological Patient-Reported Outcomes for Clinical Trials in Pediatric Patients With Sickle Cell Disease. 13,
- 108 High risk and low prevalence diseases: Acute chest syndrome in sickle cell disease. **2022**, 58, 235-244
- 107 Regional anesthesia and analgesia in sickle cell pain episodes: A scoping review. **2022**, 1, 100108
- 106 Sickle Cell Disease and Kidney. **2022**, 29, 141-148.e1 1
- 105 Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso-occlusive episodes during the randomized, open-label HELPS study.
- 104 Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease. **2022**, 11, 3986 0
- 103 Sickle Cell Disease in Children: Knowledge and Home-Based Management Strategies among Caregivers at a Tertiary Facility in Northern Ghana. **2022**, 2022, 1-6 0
- 102 Implementation of national blood conservation recommendations at an adult sickle cell center. 0
- 101 Phenotypes of sickle cell intensive care admissions: an unsupervised machine learning approach in a single-center retrospective cohort.
- 100 Early hydroxyurea use is neuroprotective in children with sickle cell anemia. 0
- 99 Sickle cell disease, thalassemia, and hereditary hemolytic anemias. **2022**, 326-345
- 98 Chronic anemia: The effects on the connectivity of white matter. 13,
- 97 Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials. **2022**, 27, 211-224 0
- 96 Prise en charge d'un patient drpanocytaire aux urgences. **2022**, 12, 234-240
- 95 Clinical features at diagnosis of sickle cell disease prior to universal newborn screening in Alberta.
- 94 Sickle cell bone disease and response to intravenous bisphosphonates in children.
- 93 High incidence of suicidal ideation in a series of sickle cell patients after hematopoietic stem cell transplantation.

- 92 Development of a Flow Phantom for Transcranial Doppler Ultrasound Quality Assurance. **2022**,
- 91 A novel, effective, and efficient strategy for treating sickle cell vaso-occlusive events in the infusion center setting.
- 90 Reassessing the Need for Preoperative Transfusions in Sickle Cell Disease Patients with an Elevated Baseline Hemoglobin Retrospective Study. Publish Ahead of Print,
- 89 Lidocaine and Ketamine Infusions as Adjunctive Pain Management Therapy: A Retrospective Analysis of Clinical Outcomes in Hospitalized Patients Admitted for Pain Related to Sickle Cell Disease. 3, 1
- 88 Internalizing Symptoms in Adolescents With Sickle Cell Disease.
- 87 Algorithm-based selection of automated red blood cell exchange procedure goals reduces blood utilization in chronically transfused adults with sickle cell disease. 1
- 86 Tailored Parenting Plans of Young Adults With Sickle Cell Disease or Sickle Cell Trait. Publish Ahead of Print, 0
- 85 Bringing Sickle-Cell Treatments to Children in Sub-Saharan Africa. **2022**, 387, 488-491 1
- 84 Precision Medicine and Sickle Cell Disease. **2022**, 6, e762 0
- 83 Age- and sex-specific rates of gall bladder disease in children with sickle cell disease. 0
- 82 Effective therapies for sickle cell disease: are we there yet?. **2022**, 0
- 81 What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel.
- 80 Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Following Implementation of the 13-Valent Pneumococcal Conjugate Vaccine in France. **2022**, 5, e2225141 1
- 79 The effect of intensity of conditioning regimen on the outcome of HSCT in children with sickle cell disease. 0
- 78 Hemoglobinopathies and Thalassemias. **2023**, 143-172
- 77 Case 6: Sickle Cell Disease. **2022**, 81-86 0
- 76 Sickle cell disease: The importance of awareness and early detection of ocular manifestations. **2022**, 4, 34 0
- 75 Sickle Cell Disease. **2022**, 653-663 0

- 74 Sickle Cell Nephropathy in Children. **2022**, 735-749 ○
- 73 COVID-19 Pandemic Impact on Implementation of mHealth to Improve Uptake of Hydroxyurea in Sickle Cell Disease: A Mixed-Methods Evaluation (Preprint). ○
- 72 Acute and chronic pain management in patients with sickle cell disease in the modern era: A comprehensive review. **2022**, 103533 ○
- 71 Adverse events of red blood cell transfusions in patients with sickle cell disease. **2022**, 103557 ○
- 70 Sickle Cell Disease and Its Respiratory Complications. **2022**, ○
- 69 Complications aiguës des syndromes drépanocytaires majeurs: expérience de l'hôpital d'Instruction des armées Omar Bongo Ondimba. **2022**, 34, 82-91 ○
- 68 Development and characterization of a preclinical total marrow irradiation conditioning-based bone marrow transplant model for sickle cell disease. 12, ○
- 67 Incidence, kinetics, and risk factors for intra- and extracranial cerebral arteriopathies in a newborn sickle cell disease cohort early assessed by transcranial and cervical color Doppler ultrasound. 13, ○
- 66 Chronic red cell exchange in sickle cell patients with iron overload may not affect mortality. 9, ○
- 65 Vital Signs: Use of Recommended Health Care Measures to Prevent Selected Complications of Sickle Cell Anemia in Children and Adolescents [Selected U.S. States, 2019]. **2022**, 71, 1241-1246 ○
- 64 Comprehensive guide to managing a chronic automated red cell exchange program in sickle cell disease. **2022**, 37, 497-506 ○
- 63 Sickle cell disease chronic joint pain: Clinical assessment based on maladaptive central nervous system plasticity. 9, ○
- 62 Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center. ○
- 61 Rates of Opioid Misuse Amongst Patients Receiving Pain Management for Sickle Cell Disease in An Urban Setting. 089719002211283 ○
- 60 A multi-disciplinary, comprehensive approach to management of children with heterotaxy. **2022**, 17, 2
- 59 Acute Care Physical Therapy and Sickle Cell Disease. Publish Ahead of Print, ○
- 58 Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis. ○
- 57 Fertility preservation for pediatric patients with hemoglobinopathies: Multidisciplinary counseling needed to optimize outcomes. 13, ○

- 56 A Versatile and Efficient Novel Approach for Mendelian Randomization Analysis with Application to Assess the Causal Effect of Fetal Hemoglobin on Anemia in Sickle Cell Anemia. **2022**, 10, 3743 ○
- 55 Effect of Blood Transfusion on Cerebral Hemodynamics and Vascular Topology Described by Computational Fluid Dynamics in Sickle Cell Disease Patients. **2022**, 12, 1402 ○
- 54 Working memory and school readiness in preschool children with sickle cell disease compared to demographically matched controls. ○
- 53 The consortium on newborn screening in Africa for sickle cell disease: study rationale and methodology. ○
- 52 Sickle cell disease in gulf cooperation council countries: a systematic review. **2022**, 15, 893-909 1
- 51 Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, in Children with Sickle Cell Disease (PNEU-SICKLE). ○
- 50 Barriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators. **2022**, 10, 2223 ○
- 49 Occult ischemic bone lesions in children with sickle cell disease: a study of prevalence. ○
- 48 Sickle Cell Disease Pathophysiology and Related Molecular and Biophysical Biomarkers. **2022**, 36, 1077-1095 ○
- 47 Sickle Cell Disease and the Kidney. **2022**, 36, 1239-1254 ○
- 46 Go the Distance. **2022**, 36, 1255-1270 ○
- 45 The Cardiopulmonary Complications of Sickle Cell Disease. **2022**, 36, 1217-1237 ○
- 44 The Evolving Landscape of Drug Therapies for Sickle Cell Disease. **2022**, 36, 1285-1312 ○
- 43 Kruppel-like factor 1-GATA1 fusion protein improves the sickle cell disease phenotype both in vitro and in vivo. ○
- 42 IF IM in a crisis: Intranasal fentanyl versus intravenous morphine in adult vaso-occlusive crisis. **2023**, 64, 86-89 2
- 41 The interplay of sleep disordered breathing, nocturnal hypoxemia, and endothelial dysfunction in sickle cell disease. **2023**, 68, 101602 ○
- 40 Complete resolution of stage II avascular necrosis affecting three joints by hyperbaric oxygen in a patient with sickle cell disease: A case report. 9, ○
- 39 Development of curative therapies for sickle cell disease. 9, 1

- 38 The impact of Hydroxyurea on the rates of Vasoocclusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study. **2022**, 22,
- 37 Diagnostic Test Accuracy of Lung Ultrasound for Acute Chest Syndrome in Sickle Cell Disease: A Systematic Review and Meta-analysis. **2022**,
- 36 Social inequalities in the temporal trend of mortality from sickle cell disease in Brazil, 1996-2019. **2023**, 39,
- 35 De patiënt met koorts en algehele malaise. **2023**, 411-428
- 34 Intraindividual pain variability metrics for youth with sickle cell disease: Relations to health outcomes.
- 33 Prevalence and Risk Factors for Pulmonary Embolism in Pediatric Sickle Cell Disease: A National Administrative Database Study. 1-13
- 32 Impact of Hydroxyurea Starting Dose on Pain Outcomes in Patients with Sickle Cell Disease. **2022**, 36, 223-227
- 31 Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
- 30 Predicting Pain in People with Sickle Cell Disease in the Day Hospital Using the Commercial Wearable Apple Watch (Preprint).
- 29 Predicting Pain in People with Sickle Cell Disease in the Day Hospital Using the Commercial Wearable Apple Watch (Preprint).
- 28 Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease. 2,
- 27 Complementary and alternative medicine for children with sickle cell disease: A systematic review. **2023**, 101052
- 26 Prise en charge pharmaceutique du patient adulte drpanocytaire. **2023**,
- 25 The Kidney in Sickle Cell Disease. **2023**, 849-863
- 24 Social determinants of neurocognitive and academic performance in sickle cell disease. **2023**, 70,
- 23 Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps.
- 22 A systematic review on hydroxyurea therapy for sickle cell disease in India. **2022**, 156, 299
- 21 Oral manifestations and management of sickle cell disease: a literature review. **2022**, 5, e84-e84

- 20 Red blood cell alloantibodies in paediatric transfusion in sub-Saharan Africa: A new cohort and literature review. ○
- 19 Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular level. **2023**, 27, 133-149 ○
- 18 Neuromonitoring in Children with Cerebrovascular Disorders. **2023**, 38, 486-503 ○
- 17 Management of Older Adults with Sickle Cell Disease: Considerations for Current and Emerging Therapies. **2023**, 40, 317-334 ○
- 16 Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. **2023**, 10, e261-e271 ○
- 15 Angiotensin and pain. **2023**, 597-622 ○
- 14 Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. **2023**, 2023, ○
- 13 Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study. 106-117 ○
- 12 High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study. 174-184 ○
- 11 Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges. ○
- 10 High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study. 174-184 ○
- 9 Efficacy and safety of pharmacological interventions for managing sickle cell disease complications in children and adolescents: Systematic review with network meta-analysis. ○
- 8 Challenges in the treatment of melanoma with BRAF and MEK inhibitors in patients with sickle cell disease: case report and review of the literature. **2023**, 14, 204062072311559 ○
- 7 Sickle Cell Disease Knowledge and Reproductive Decisions: A Saudi Cross-Sectional Study. Volume 17, 761-767 ○
- 6 Pain Management. **2017**, 423-460.e12 ○
- 5 Successful quality improvement project to increase hydroxyurea prescriptions for children with sickle cell anaemia. bmjqs-2022-015209 ○
- 4 Efficacy of non-pharmacological interventions to reduce pain in children with sickle cell disease: A systematic review. ○
- 3 A randomized controlled trial to examine the effect of the Pediatric Opioid Analgesia Self-Instruction System (PedOASIS) tool on pediatric hematology/oncology trainee education. ○

- 2 Manifestations respiratoires de la drpanocytose. **2023**, ○
- 1 Advances in the Diagnosis and Treatment of Pediatric Arterial Ischemic Stroke. ○